Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 2 of 3 of List of References

LIST OF	<b>REFERENCES</b>	CITED BY	APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ARTUNIT
June 4, 2001	1643

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A31	5,947,646	07/19/99	Srivastava et al.	
	A32	5,968,526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
· · · · · · · · · · · · · · · · · · ·	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
W	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A42	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	,
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713.608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
-	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
<del></del>	A56	7.132.109	11/07/06	Srivastava	N. O

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 3 of 3 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT Srivastava et al.		
(Use several sheets if necessary)			
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

B01	DE 196 02 985 A1	1/27/96	Germany	
	GB 2 251 186A	7/1/92	United Kingdom	
B02	<u> </u>			
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B06	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
BII	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center University of Conneticut Health	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center University of Conneticut Health	
B20	WO 04/035602	04/29/04	Center University of Conneticut Health University of Conneticut Health	
B21	WO 04/075636	09/10/04	Center University of Conneticut Health	
B22	WO 04/74454 WO 05/120558	09/02/04	Center University of Conneticut Health	
B23			Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

	EXAMINER				
--	----------	--	--	--	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

#### FOREIGN PATENT DOCUMENTS WO 90/02564 3/22/90 Codon Dragon B25 WO 91/15572 10/17/91 The Wellcome Foundation Limited **B26** WO 92/01717 2/6/92 Burnie, James et al. **B27** WO 92/08484 5/29/92 University College London **B28** WO 92/08488 5/29/92 University College London B29 WO 93/14118 7/22/93 Medical Research Council B30 WO 93/17712 9/16/93 Biocine Sclavo Spa Rappuoli B31 WO 93/18146 9/16/93 Institut National de la Sante et de la B32 researche medicale WO 93/18147 9/16/93 Institute Nazionale per lo studio e la B33 cura dei tumori fondazione giovanni pascale WO 93/18150 9/16/93 Biocine S.P.A. **B34** 10/28/93 WO 93/21529 **Duke University B35** WO 93/24136 12/9/93 Terman, David S. **B36** Yeda Research and Development WO 94/03208 2/17/94 **B37** Company, Ltd WO 94/04676 3/3/94 The Victoria University of Manchester **B38** WO 94/11513 5/26/94 Medical Research Council Colston B39 WO 94/14471 7/7/1994 Washington University B40 WO 94/29459 12/22/94 Whitehead Institute for Biomedical B41 Research The American National Red Cross -B42 WO 97/04794 2/13/97 The General Hospital Corporation WO 97/06685 2/27/97 Sloan-Kettering Institute for Cancer **B43** Research WO 97/06821 2/27/97 Sloan-Kettering Institute for Cancer **B44** Research WO 97/06828 2/27/97 Sloan-Kettering Institute for Cancer **B45** Research WO 97/10001 03/20/97 Fordham University B48 WO 97/26910 7/31/97 Max-delbruck medizen milleck **B47** WO 98/42752 10/01/98 **B**48 Brigham and Woman's Hospital Inc. Juridicial Foundation the Chemo-Sero-WO 98/46739 7/23/97 **B**49 therapeutic Research Institute WO 99/29834 06/17/99 Fordham University **B50**

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ARTUNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
nttais	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	CI0	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
, , , , , , , , , , , , , , , , , , , ,	CH	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"  American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
, ()	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" <i>J. Exp. Med.</i> 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER	DATE CONSIDERED
ACTION AND A STATE OF THE STATE	and with MDED 600. Draw line through sitation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

	ATTY: DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
,	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
· •	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	T
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	t

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403 APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

Examiner			
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
• •	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
·_ <del></del>	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C55	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C55	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	Τ
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	
	C61	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

	EXAMINER	DATE CONSIDERED
--	----------	-----------------

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403			
APPLICANT Srivastava et al.			
FILING DATE	ART UNIT		
	APPLICANT Srivastava et al.		

	т		
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	$ _{T}$
iiiiais	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	十
	1007	Science 245:385-390	
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730	$\top$
<del> </del>	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and	+
		chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New	+
		York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid	1
	0.0	leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-	T
		55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae	
		provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	1
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae	T
		multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell	T
		membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	}
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat	T
		shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun.	1
		60(7):2565-71	
	C77	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum	Т
		protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in	
	1	Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine	
		B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric	Γ
		focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines	П
		against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North	
		America, Vol. 52:839-846	L
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of	
		Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	L
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites",	
		Science Vol. 250 113-116	L
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and	Γ
		endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-	
		16737.	1
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	╁

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.			
	FILING DATE June 4, 2001	ART UNIT 1643		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т		
Initials	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera." Biochem, Mol. Biol. Int. 37(5):917-23			
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27			
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910			
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784			
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.			
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.			
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.			
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869			

EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

	ATTY, DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	HOUGHTEN et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
C108	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
C107	
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
C109	with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	Membrane Antigen." Cancer Res. 53:227-230
CIII	
C112	1520
C113	JAMES, K., 1980, "Alpha (2) macroglobulin and its possible importance in immune systems," Trends in Biol. Sci. p.43-47
C114	protein gp96 preparations: a pilot study" Int. J. of Cancer 88:232-238
	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	JOCHAM et al., 2004, "Adjuvant Autologous Renal Tumour Cell Vaccine and Risk of Tumour Progression in Patients with Renal-Cell Carcinoma After Radical Nephrectomy: Phase III, Randomised

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u>

Sheet 2 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

Lavo	TATO AND A 1 2000 WA marketing of Tumor Ligate Immunogancity by agrichment of Changrana
C119	Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol. 19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, Abstract #5516
	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
	KOO, 1982, "Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice," Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	53:1333-1336
	KRISTENSEN et al., 1990, "Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C135	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C134	induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	

EXAMINER DATE CONSIDERED
--------------------------

Express Mail No.: <u>ED 608 969 361 US</u>

Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis,
	Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
	46:2189-2192
C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor
	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	
	in General", Career Surveys 13:81-99
C145	
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an
	idea whose time has come" Semin. in Oncology 25:654
C147	
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	
C140	Clin. Apheresis 1: 25-32  MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer,"
(149	Biotherapy 10:173-185
C150	MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin
(150	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
	differentiation antigen", Exper. Cell Res. 190: 195-203.
CISI	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin
Cisi	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides
	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	
CIE	Recombinant Interleukin-2", Science 225:1487-1489  MUNRO et al., 1986, "An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein
C155	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	
C130	Studies." Cancer 40:680-686
C157	
137	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
CISS	NAIR et al., 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses
[ 138	against bound peptides" J. Immunol. 162:6426
C159	
(0.13)	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer,
	59:55-63

MEVANGINED. Initial if a farmers assertioned subather or not citation is in conformance with MDED 600; Drow line through citation if not in conformance and not
---

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

			_
C	C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	L
C	2161	NORRBY, 1985, "Summary," in: <i>Vaccines 85</i> , Lerner <i>et al.</i> , eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY pp. 387-394	
(	C162	OETTGEN AND OLD, 1991 "The History Of Cancer Immunotherapy." In: Introduction To The Biologic Therapy Of Cancer". Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	
(	C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00	Ι
		OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	L
(	C165	OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625.137 filed 07/25/00	ļ.
(	C166	OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00	Ļ
	C167	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00	l
	C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	T
	C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00	Ī
(	C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	t
	C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00	T
	C172		Ť
	C173	OFFICE ACTION mailed on 09/21/06 for U.S. Application No. 09/668,724 filed 09/22/00	T
- (	C174		t
	C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	t
	C176		T
	C177		T
(	C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02	t
(	C173	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02	
(	C186	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	
(	C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
(	C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427.857 filed 05/01/03	
(	C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05	
(	C184	OFFICE ACTION mailed on 02/22/07 for U.S. Application No. 10/784,012 filed 02/20/04	ļ
	C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
(	C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	
	C187		Τ
		receptor-4 complex. J. Immunol. 164:558-561	ļ
	C188	OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced	
		Tumors." Ann. N.Y. Acad. Sci. <u>101</u> :80-106	1
	C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection."	
		Aliment Pharmacol Ther. 13(1):35-42.	
7	C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces	T
		cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary	
		tuberculosis." Infect Immun. 60(11):4781-92	

EXAMINER	DATE CONSIDERED			
*EVAMINED. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not				

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	8449-178-999	09/873,403	
	APPLICANT		
	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

C101	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
(19)	BALB/c sarcomas", Cancer Research 47:5074-5079
C193	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62
C192	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity
(19.	Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and
	Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
C10/	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-
(192	
CIO	220 Cited On pp.1173-1174  PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
C195	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No.
C 190	
CIO	PCT/US03/14390 PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No.
(19)	
C100	PCT/US01/23098
198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No.
	PCT/US01/18041 PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No.
199	
G20/	PCT/US02/26573 PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No.
C200	
G20	PCT/US2004/005110
C20	
C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by
	ADP-affinity chromatography" J. Immunol. Meth. 204:13
C20.	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4
	Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
C20	
4	heat shock protiens", Nature Vol 320 (13) 182-184
C200	
	oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C20	PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst.
	<u>18</u> :769-778
C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C20	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol.
[ 20.	3(2):139-54
C210	REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator
(21)	in treated patients." Thromb Haemost. 64(2):276-80.
C21	
	Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C21	
	and Related Techniques, December 1984
C21	
	transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-
1	induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796

	EXAMINER	DATE CONSIDERED
ł	*EVAMINED: Initial if reference considered, whether or not citation is in confor	mance with MPEP 609. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	La company and Pelated
C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized
(213	by Cytotoxic T cells" Nature 348:248-251
C216	Car u
(210	including H-4 and H-Y" Science 249: 283-287
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C218	SALLUSTO et al 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is
	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by
	tumor necrosis factor alpha." J. Exp. Med. 179(4):1109-1118
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide
	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-
	reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary
	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med.
	191:423-434
C221	A TO A TO A CONTRACT OF A CONT
	923-955
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on
	HLA Class I and Class II," J. Immunol. 173:1987-1993
C224	SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting
	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C225	SINGH, 1997, "Neuroautoimmunity: pathogenic implications for Alzheimer's disease," Gerontology
	43:79-94
C226	
	Carcinoma Patients." Scand J. Immunol 33:699-706
C229	
	hsp90", J. Mol. Biol. 194(2):341-4
C229	
	Acta. Neurol. Scand. 98(5):314-7
C229	
	111:1057-1062
C230	SPERO et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for
	Surgical Procedures," 19-22
C231	SRIVASTAVA and HEIKE, 1986, "Tumor-specific immunogenicity of stress-induced proteins:
	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
C232	1
	Tumor Antigens and Specific Tumor Therapy, pages 63-71
C233	
	Curr. Opin. Immunol. 6:728
C234	
1	Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C235	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C236	
C237	
C238	
C239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
C240	
C241	adaptive world", Immunity 8(6):657-65
C242	Experientia. (11-12):1054-60
C243	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C244	SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev. Immunol. 2(3): 185-194
C245	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer," Thorax 37(8):588-593
C246	STEINMAN, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C248	<del>                                     </del>
C249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57
C250	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C251	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in: Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.), Birkhauser/Springer, 77: 451-465
C252	
C253	
C254	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
C255	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in confor considered. Include copy of this form with next communication to applicant.	mance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	
	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	
	tissue." Mol. Cell. Biochem. 18(2-3):101-7
C259	UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96,
	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the
	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein,"
	Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	
	300(6725):662-5 Review
C263	VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res.
	28:2477-2483
C264	
	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
C265	
	b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
C266	
	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as
	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
	497
C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of
	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	
C270	
C271	
6070	257:14949-14959  WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the
C272	
6272	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes
	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
	fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	
C275	
	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	
C277	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u>

		Sheet 9 of 9 of List of References
	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.	
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540	
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" <i>Int. J. Mol. Med.</i> 3:243	
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627	
C282		
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.	

EXAMINER	DATE CONSIDERED



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 1 of 3 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE
June 4, 2001

ART UNIT

1643

#### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	09/393,652	9/10/99	Srivastava	
	A02	2001-0034042	10/01	Srivastava	
	A03	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	A11	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
····-	A28	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u>

APPLICATION NO.

1643

Sheet 2 of 3 of List of References

	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ARTUNIT

ATTY. DOCKET NO.

June 4, 2001

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INTIAL	A31	5,947,646	07/19/99	Srivastava et al.	11001000 1111
	A32	5,968,526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
-	A56	7,132,109	11/07/06	Srivastava	

EX	ΔN	ΑT	NI	R

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 3 of 3 of List of References

#### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	
FILING DATE June 4, 2001	artunit 1643

		FOREIGN	N PATENT DOCUMENTS	
B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B06	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
BII	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.			
	8449-178-999	09/873,403			
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT				
(Use several sheets if necessary)	Srivastava et al.				
	FILING DATE	ARTUNIT			
	June 4, 2001	1643			

T	WO 90/02564	3/22/90	Codon Dragon	
B25				
B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
B27	WO 92/01717	2/6/92	Burnie, James et al.	
B28	WO 92/08484	5/29/92	University College London	
B29	WO 92/08488	5/29/92	University College London	
B30	WO 93/14118	7/22/93	Medical Research Council	
B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
B34	WO 93/18150	9/16/93	Biocine S.P.A.	
B35	WO 93/21529	10/28/93	Duke University	
B36	WO 93/24136	12/9/93	Terman, David S.	
B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
B39	WO 94/11513	5/26/94	Medical Research Council Colston	
B40	WO 94/14471	7/7/1994	Washington University	
B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
B46	WO 97/10001	03/20/97	Fordham University	
B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
B50	WO 99/29834	06/17/99	Fordham University	

EV	ARA	IINI	7 D
H.X.	AIV	III	ıк

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

•	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	_
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	T	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
muais	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"  American Society Clinical Oncology Meeting, abstract 1278	
= **	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	<u> </u>
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
·	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" <i>J. Exp. Med.</i> 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not	
considered. Include copy of this form with next communication to applicant		

•	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	T
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	T

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	mance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT	ATTY. DOCKET NO.  8449-178-999  APPLICANT	APPLICATION NO. 09/873,403
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	-r		т-
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1,
IIIIIII	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	T
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses	╁
	C46	64(3):458-463	
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol.	Τ
		Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast	T
		cancers	┸
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia	
		30;50(11-12):1061-6	┸
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	1
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells,"	T
		Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation	Τ
		Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	╧
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor	
		associated protein." Eur. J. Biochem 244:544-51	┵
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann.	Ì
		Neurol. 41(3):341-52.	1
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	1
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-	1
		associated antigen p97," J. Natl. Cancer Inst. 81:445-448	+
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	+
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I	l
	000	Molecules", Nature 348:248-251  FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification	+
	C62	in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC	╁
	1003	Molecules", Nature 351:290-296	
	C61	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved	+
	1001	between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)",	✝
		Blood 54: 747-749	
	C56	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor	1
		rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the	1
		immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting,	
		Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against	
		mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	$\perp$

|--|

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	artunit 1643	

Examiner			
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	ľ
	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	
		Science 245:385-390	╀
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	1
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-	
,	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	T
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C76	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	Ī
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	T
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	Ī
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	Ī
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	T
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	T
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	Ť

	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243
EXAMINE	ER .	DATE CONSIDERED
		all if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	103.0.03,.00	
	FILING DATE June 4, 2001	art unit 1643	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
Intials	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera," Biochem. Mol. Biol. Int. 37(5):917-23		
···	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27		
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." <i>Biochem. Biophys. Res. Comm.</i> 160:903-910		
."- '	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784		
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.		
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.		
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.		
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869		

EXAMINER	DATE CONSIDERED
WEY AMINED. Initial if reference considered, whether or not citation is in conform	pance with MPEP 609. Draw line through citation if not in conformance and not



### LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
Tune 4 2001	1643

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	
C103	
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
	HUGHES et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
C107	
C108	Y
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	
C113	Biol. Sci. p.43-47
C114	
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	
C118	

#### EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
·	FILING DATE June 4, 2001	ART UNIT 1643

C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, Abstract #5516
C124	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
	KOO, 1982, "Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice," Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	KRIPKE, 1974 "Antigenicity Of Murine Skin Tumors Induced By Ultraviolet Light." J. Natl. Cancer Inst. 53:1333-1336
	KRISTENSEN et al., 1990, "Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
C132	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", <i>EMBO J.</i> 12(8):3143-3151
C134	Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
	MADDEN et al., 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

10140	MANI (1001) Willia Human Hamplague of the Mouse Turner Delection Assign CD06" Db D thesis
C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
141	46:2189-2192
C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor
[6.72	harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	
	in General", Career Surveys 13:81-99
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation
	for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American
	Society for Microbiology pp. 1-13
C146	
	idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not
	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C149	MILLWARD AND HOELTGE, 1982, "The Historical Development of Automated Hemapheresis", J. of
	Clin. Apheresis 1: 25-32
C149	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer,"
	Biotherapy 10:173-185
C150	
	receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte
	differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin
	receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	
[ 132	Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	
[ 6.5.	Recombinant Interleukin-2", Science 225:1487-1489
C155	
	and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	
	Studies." Cancer 40:680-686
C157	
	Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	
	against bound peptides" J. Immunol. 162:6426
C159	NATALI et al., 1987 "Immunohistochemical Detection Of Antigen In Human Primary And Metastatic
	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer,
	59:55-63

	C139	Melanomas By The Monoclonal Antibody 140.240 And Its Possible Prognostic Significance." Cancer, 59:55-63
EXAMINER		DATE CONSIDERED
		if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
	C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the	_
		stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	
	C161	NORRBY, 1985, "Summary," in: Vaccines 85, Lerner et al., eds., Cold Spring Harbor Laboratory, Cold	
		Spring Harbor, NY pp. 387-394	_
	C162		
		Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	
	C163		_
	C164		
	C165		
	C166	OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00	
	C167	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00	
	C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	
-	C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00	
	C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	
	C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00	_
	C172		
	C173		
<u></u>	C174		
		OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	
	C176		
	C177		
	C178		
	C179		
	C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	
	C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
	C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	
	C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05	
	C184	OFFICE ACTION mailed on 02/22/07 for U.S. Application No. 10/784,012 filed 02/20/04	
	C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
	C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	_
-	C187	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like	
		receptor-4 complex. J. Immunol. 164:558-561	
	C188		
		Tumors." Ann. N.Y. Acad. Sci. 101:80-106	
	C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection."	
		Aliment Pharmacol Ther. 13(1):35-42.	
	C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces	_
		cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary	
		tuberculosis." Infect Immun. 60(11):4781-92	

## \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

	1 0101	DAYY A DIVO 1 1 1007 WE are in a fabored tumor cropific entired by two chemically induced
		PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", Cancer Research 47:5074-5079
	C192	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62
	C193	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and
		Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
		PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189- 220 Cited On pp.1173-1174
	C195	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
	C196	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390
		PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098
	C198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041
	C199	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573
	C200	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
	C201	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
-0,5-	C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography" J. Immunol. Meth. 204:13
	C203	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4 Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
	C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
	C205	PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major heat shock protiens", Nature Vol 320 (13) 182-184
		PINILLA-Ibarz et al., 2000, "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
	C207	PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778
	C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
	C209	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54
	C210	REED et al., 1990, "Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients." Thromb Haemost. 64(2):276-80.
	C211	REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific- Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
	C211	REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis and Related Techniques, December 1984
	C213	ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.			
	FILING DATE June 4, 2001	ART UNIT 1643		

	NON PATENT LITERATURE DOCUMENTS	
	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601	
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", <i>Nature</i> 348:248-251	
C216	ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides including H-4 and H-Y" Science 249: 283-287	
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272	
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118	
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184	
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434	
C221	923-955	
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706	
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA Class I and Class II," J. Immunol. 173:1987-1993	
C224	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8	
C225	43:79-94	
C226	Carcinoma Patients." Scand J. Immunol 33:699-706	
C227	SORGER and PELHAM, 1987, "The glucose-regulated protein grp94 is related to heat shock protein hsp90", J. Mol. Biol. 194(2):341-4	
C228	Acta. Neurol. Scand. 98(5):314-7	
C229	111:1057-1062	
C230	Surgical Procedures," 19-22	
C231	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64	
C232	Tumor Antigens and Specific Tumor Therapy, pages 63-71	
C233	Curr. Opin. Immunol. 6:728	
C234	SRIVASTAVA et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314	

EXAMINER	DATE CONSIDERED

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
· · · · · · · · · · · · · · · · · · ·	C235	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422	
	C236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811	
	C237	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse tumors." Immunol, Today 9:78-83	
	C238		
	C239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658	
	C240		
	C241	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world", Immunity 8(6):657-65	
	C242	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm", Experientia. (11-12):1054-60	
	C243	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177	
	C244	SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev. Immunol. 2(3): 185-194	
	C245	cancer," Thorax 37(8):588-593	
	C246	encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30	
	C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6	
	C248	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8 Review	
•	C249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57	
	C250	histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51	
	C251	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in: Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.), Birkhauser/Springer, 77: 451-465	
	C252	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1" p24. J Immunol. 156(2):873-9	
	C253		
	C254		
	C255	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872	

EXAMINER	DATE CONSIDERED
	in MDFD (00 Day Unabanda in in in an forman and an
*EXAMINER: Initial if reference considered, whether or n	t citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

	ATTY. DOCKET NO. APPLICATION NO. 09/873,403			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.			
	FILING DATE June 4, 2001	ART UNIT 1643		

C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
6250	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines
	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast
	tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	
	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the
	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein,"
	Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	
	300(6725):662-5 Review
C264	VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res.
	<u>28:2477-2483</u>
C264	
	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
C265	
6266	b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380  WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility
C266	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	
C207	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
	497
C268	
	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
C270	
C271	
(271	257:14949-14959
C272	WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the
	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes
	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
	fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
C275	WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin
	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C275	WONG et al., 1991, "Susceptibility to type I diabetes in women is associated with the CD3 epsilon locus
	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.	
	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540	
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" Int. J. Mol. Med. 3:243	
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627	
C282		
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.	

EXA	MIN	ER

DATE CONSIDERED





Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 1 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
3.1.1.0.0.1.0.0.1.0.0.1.0.0.1.0.0.0.1.0	
FILING DATE	ART UNIT
June 4, 2001	1643

*EXAMINER		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	09/393,652	9/10/99	Srivastava	
	A02	2001-0034042	10/01	Srivastava	
	A03	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	,
	A07	2002-0192230	12/19/02	Srivastava	
	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	All	2004-0253228	12/16/04	Srivastava	
	All	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	<u> </u>	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
	A28	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

#### **EXAMINER**

DATE CONSIDERED



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 2 of 3 of List of References

ATTY. DOCKET NO. APR 8449-178-999 09

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE
June 4, 2001

ART UNIT

#### U.S. PATENT DOCUMENTS PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT \*EXAMINER FIGURES APPEAR DATE NAME INITIAL DOCUMENT NUMBER 5,947,646 07/19/99 Srivastava et al. A31 A32 5,968,526 10/19/99 Garman et al. 12/7/99 Srivastava et al. 5,997,873 A33 12/28/99 Srivastava et al. A34 6,007,821 2/22/2000 Pauza 6,027,731 A35 02/29/00 Srivastava 6,030,618 A38 6.033,561 3/7/2000 Schoendorfer A37 6,048,530 4/11/00 Srivastava A38 10/24/00 Srivastava 6,136,315 A38 12/05/00 Strickland et al. A40 6.156.311 6,162,436 12/19/00 Srivastava A41 1/2/01 Srivastava et al. 6,168,793 A42 6,312,711 11/6/01 Duchateau et al. A43 6.333,311 12/25/2001 Nuijens et al. A44 01/15/02 Nicolette 6,338,945 A45 6,403,092 6/11/02 Pizzo et al. A46 Wallen et al. 6,433,141 8/13/02 A47 02/10/04 Sette et al. 6,689,363 A48 Henot et al. 3/23/04 6,709,672 A49 Wallen et al. 6,713,608 3/30/04 A50 6,730,302 5/4/04 Fujihara et al. A51 9/28/04 Srivastava 6,797,480 A52 01/06 Li 6,986,389 A53 03/06/07 7,176,515 Srivastava et al. A54 7,179,462 02/20/07 Srivastava et al. A55 11/07/06 Srivastava 7,132,109 A56

#### **EXAMINER**

DATE CONSIDERED



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 3 of 3 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE

June 4, 2001

ART UNIT

B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B08	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
В09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

## **EXAMINER**

DATE CONSIDERED

Sheet 1 of 3 of List of References

ATTY. DOCKET NO.	APPLICATION NO.	
8449-178-999	09/873,403	
APPLICANT		
Srivastava et al.		
FILING DATE	ART UNIT	
June 4, 2001	1643	

# LIST OF REFERENCES CITED BY APPLICANT

(Use several shorts if necessary)

NOV 0 8 5007

#### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
HAITIAL	A01	09/393,652	9/10/99	Srivastava	
	A02	2001-0034042	10/01	Srivastava	
-	A03	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	All	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
	A24	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
. ***	A27	5,846,928	12/8/1998	Kishida	
	A28	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

## **EXAMINER**

DATE CONSIDERED

Sheet 2 of 3 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	l
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		_
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

PAGES, COLUMNS, LINES, WHERE					
*EXAMINER		DOCUMENT 100 (DET	D. A. COLO	NAME	RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
INITIAL	A31	5,947,646	07/19/99	Srivastava et al.	FIGURES AFFEAR
	A32	5,968,526	10/19/99	Garman et al.	
	A33	5,997,873	12/7/99	Srivastava et al.	
	A34	6,007,821	12/28/99	Srivastava et al.	
	A35	6,027,731	2/22/2000	Pauza	
	A36	6,030,618	02/29/00	Srivastava	
	A37	6,033,561	3/7/2000	Schoendorfer	
	A38	6,048,530	4/11/00	Srivastava	
	A39	6,136,315	10/24/00	Srivastava	
	A40	6,156,311	12/05/00	Strickland et al.	
	A41	6,162,436	12/19/00	Srivastava	
	A42	6,168,793	1/2/01	Srivastava et al.	
	A43	6,312,711	11/6/01	Duchateau et al.	
	A44	6,333,311	12/25/2001	Nuijens et al.	
	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
	A56	7,132,109	11/07/06	Srivastava	

TO TO	A B 4	TATE	T
EX.	/AIVI	LINE	·K

DATE CONSIDERED

Sheet 3 of 3 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

B01	DE 196 02 985 AI	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	•
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	

## **EXAMINER**

DATE CONSIDERED

Sheet 1 of 3 of List of References

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	
FILING DATE	ART UNIT
June 4, 2001	1643

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

- NOA 0 8 5003 B

	U.S. ATENT DOCUMENTS  PAGES COLUMNS LINES WHERE					
*EXAMINER		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
INITIAL	A01	09/393,652	9/10/99	Srivastava		
	A02	2001-0034042	10/01	Srivastava		
	A03	2002-0001841	1/03/02	Kaltoft et al.		
<u>.</u>	A04	2002-0028207	6/4/01	Srivastava		
	A05	2002-0037290	03/28/02	Armen		
·····	A06	2002-0172682	11/21/02	Srivastava		
	A07	2002-0192230	12/19/02	Srivastava		
	A08	2003-0129296	07/10/03	Srivastava		
	A09	2003-0211971	11/13/03	Srivastava		
•	A10	2004-0022796	02/05/04	Srivastava		
	All	2004-0253228	12/16/04	Srivastava		
	A12	2006-0165710	07/26/06	Srivastava		
	A13	4,690,915	9/1/87	Rosenberg		
	A14	5,112,298	5/12/1992	Prince et al.		
	A15	5,188,964	2/23/93	McGuire et al.		
	A16	5,232,833	8/3/93	Sanders et al.		
	A17	5,273,965	12/28/93	Kensil et al.		
	A18	5,348,945	9/20/94	Berberian et al.		
	A19	5,554,293	9/10/1996	Uhoch		
	A20	5,580,859	12/3/96	Felgner et al.		
	A21	5,637,082	6/10/1997	Pages et al.		
	A22	5,652,115	7/29/97	Marks et al.		
	A23	5,736,146	4/7/98	Cohen		
	A24	5,747,332	5/5/98	Wallen et al		
	A25	5,750,119	05/12/98	Srivastava		
	A26	5,830,464	11/03/98	Srivastava et al.		
	A27	5,846,928	12/8/1998	Kishida		
	A28	5,869.058	2/9/99	Cohen		
	A29	5,891,653	4/6/99	Attfield		
	A30	5,910,306	06/99	Alving et al.		
		1				

#### **EXAMINER**

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICATION NO.

Sheet 2 of 3 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ARTUNIT	
	June 4, 2001	1643	

#### **U.S. PATENT DOCUMENTS** PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT \*EXAMINER FIGURES APPEAR DOCUMENT NUMBER DATE NAME INITIAL 07/19/99 5,947,646 Srivastava et al. A31 10/19/99 A32 5,968,526 Garman et al. 12/7/99 Srivastava et al. 5,997,873 A33 12/28/99 Srivastava et al. 6,007,821 A34 6,027,731 2/22/2000 Pauza A35 6,030,618 02/29/00 Srivastava A36 3/7/2000 Schoendorfer 6,033,561 A37 4/11/00 Srivastava 6,048,530 A38 10/24/00 Srivastava 6,136,315 A39 A40 12/05/00 Strickland et al. 6,156,311 6,162,436 12/19/00 Srivastava A41 1/2/01 Srivastava et al. 6,168,793 A42 11/6/01 Duchateau et al. 6,312,711 A43 12/25/2001 Nuijens et al. 6,333,311 A44 01/15/02 6,338,945 Nicolette A45 6/11/02 Pizzo et al. 6,403,092 A46 8/13/02 Wallen et al. 6,433,141 A47 6,689,363 02/10/04 Sette et al. A48 6,709,672 3/23/04 Henot et al. A49 6,713,608 3/30/04 Wallen et al. A50 Fujihara et al. 5/4/04 6,730,302 A51 9/28/04 6,797,480 Srivastava A52 6,986,389 01/06 Li A53 03/06/07 Srivastava et al. 7,176,515 A54 02/20/07 Srivastava et al. 7,179,462 A55 7,132,109 11/07/06 Srivastava A56

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 3 of 3 of List of References

ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. APPLICATION NO. 09/873,403

APPLICANT


Srivastava et al.

FILING DATE
June 4, 2001 1643

		FOREIGN		
B01	DE 196 02 985 A1	1/27/96	Germany	
B02	GB 2 251 186A	7/1/92	United Kingdom	
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center	-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
B21	WO 04/075636	09/10/04	University of Conneticut Health Center	
B22	WO 04/74454	09/02/04	University of Conneticut Health Center	
B23	WO 05/120558	12/22/05	University of Conneticut Health Center	
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

<b>EXAMI</b>	NER
--------------	-----

DATE CONSIDERED





Sheet 1 of 6 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE June 4, 2001 ART UNIT 1643

F REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

## **FOREIGN PATENT DOCUMENTS**

B25	WO 90/02564	3/22/90	Codon Dragon	
B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
B27	WO 92/01717	2/6/92	Burnie, James et al.	
B28	WO 92/08484	5/29/92	University College London	
B29	WO 92/08488	5/29/92	University College London	
B30	WO 93/14118	7/22/93	Medical Research Council	
B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
B34	WO 93/18150	9/16/93	Biocine S.P.A.	
B35	WO 93/21529	10/28/93	Duke University	
B36	WO 93/24136	12/9/93	Terman, David S.	
В37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
B39	WO 94/11513	5/26/94	Medical Research Council Colston	
B40	WO 94/14471	7/7/1994	Washington University	
B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
B46	WO 97/10001	03/20/97	Fordham University	
B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
B50	WO 99/29834	06/17/99	Fordham University	

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: ED 608 969 358 US



Sheet 2 of 6 of List of References

## LIST OF REFERENCES CITED BY APPLICANT


(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
Tuno 4 2001	1642

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	C08	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-	Т		
<u></u>	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.			
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	1		
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"  American Society Clinical Oncology Meeting, abstract 1278			
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44			
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14			
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83			
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	Γ		
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72			
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233			
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8			
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504			
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", The Institute for Cancer Research 30:2458-2462			
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802			
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46			
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313			
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.			
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462			
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12			

### **EXAMINER**

DATE CONSIDERED



Express Mail No.: <u>ED</u>

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	C27	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides,"	Т	
<u></u>	C28	Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133  BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	+	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171		
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36		
4.7415.57PH; EVPELALAP	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502		
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356		
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23		
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs		
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8		
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147		
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415		
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288		
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679		
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860		
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227		
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324		
	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	T	
· · · · · · · · · · · · · · · · · · ·	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215		
· <del>.</del>	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.		
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	+	

EXAMINER	DATE CONSIDERED		
	·		
*FXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not			

Express Mail No.: ED 608 969 358 US Sheet 4 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	r
	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	į
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
-	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	T
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	Ī
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C55	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	Γ
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", Nature 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296	
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C\$5	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	Г

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include conv. of this form with next communication to applicant				

Express Mail No.: ED 608 969 358 US

APPLICATION NO.

1643

Sheet 5 of 6 of List of References

#### ATTY. DOCKET NO. 8449-178-999 09/873,403 LIST OF REFERENCES CITED BY APPLICANT APPLICANT (Use several sheets if necessary) Srivastava et al. FILING DATE ART UNIT

June 4, 2001

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1	(I. 1.1	T
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	┿
	C69		ı
	C70	Science 245:385-390 FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	╁
	C70	FORDESTED and 1991, Peptide-binding specificity of the Molecular Chapetone Bir , Nature 555.720-750	╀
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New	T
		York p4	┷
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid	
		leukemia," Blood 96(4):1480-1489	<u> </u>
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae	140
	10,3	provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae	+
	6,0	multiplication in mouse footpads," Infect Immun. 62(10):4250-5	1
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell	╅
	0,,	membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat	╈
		shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun.	
		60(7):2565-71	ı
	C77	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum	T
		protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in	1
		Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	1
<del></del>	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	1
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine	T
		B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric	T
		focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines	T
		against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	-
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North	T
		America, Vol. 52:839-846	1
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of	Τ
		Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites",	T
		Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and	T
		endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-	
	1	16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	+
	1009	HARLOW Ct al., 1700, Althouses. A Labolatory Mailual Cli 0.137-243	

EXAMINER	DATE CONSIDERED
*EVANAINED. Initial if reference considered, whether or not citation is in conform	names with MPER 600. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

ATTY. DOCKET NO.

8449-178-999

APPLICANT

Srivastava et al.

Filing date

June 4, 2001

APPLICATION NO.

09/873,403

ART UNIT

1643

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

		NON PATENT LITERATURE DOCUMENTS	т
Examiner Initials	-	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Inttuis	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera." Biochem, Mol. Biol. Int. 37(5):917-23	
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27	
···········	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910	
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784	
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.	
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.	
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.	
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869	

EXAMINER	DATE CONSIDERED
----------	-----------------



Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO.

8449-178-999

APPLICANT

Srivastava et al.

FILING DATE ART UNIT
June 4, 2001 1643

## IST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

### FOREIGN PATENT DOCUMENTS

	B25	WO 90/02564	3/22/90	Codon Dragon	
	B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
	B27	WO 92/01717	2/6/92	Burnie, James et al.	
	B28	WO 92/08484	5/29/92	University College London	
	B29	WO 92/08488	5/29/92	University College London	
	B30	WO 93/14118	7/22/93	Medical Research Council	
	B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
	B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
	В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
	B34	WO 93/18150	9/16/93	Biocine S.P.A.	
	B35	WO 93/21529	10/28/93	Duke University	
	B36	WO 93/24136	12/9/93	Terman, David S.	
	B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
	B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
	B39	WO 94/11513	5/26/94	Medical Research Council Colston	
	B40	WO 94/14471	7/7/1994	Washington University	
	B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
	B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
	B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
·	B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
	B46	WO 97/10001	03/20/97	Fordham University	
	B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
	B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
	B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
	B50	WO 99/29834	06/17/99	Fordham University	

EXAMINE	ł
---------	---

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials	C08	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-	Т
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase	-
<del>,</del>		and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	_
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
	CH	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"  American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EX.	٩M	INI	ER
-----	----	-----	----

DATE CONSIDERED

Express Mail No.: ED 608 969 358 US

APPLICATION NO.

Sheet 3 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	1	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	т
<u>Initials</u>	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	İ
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
***************************************	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	1
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
11.500	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	1
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	T

EXAMINER		DATE CONSIDERED	
SEVAMINED.	Initial if reference concidered, whether or not citation is in conform	nance with MPEP 600: Draw line through citation if not in conformance and not	

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T		
initiais	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	+		
			+		
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463			
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986			
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers			
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6			
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	T		
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	+		
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	Ī		
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation	T		
		Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	L		
	C55	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor			
	C57	associated protein." Eur. J. Biochem 244:544-51  EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann.	╁		
	03/	Neurol. 41(3):341-52.	ı		
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	十		
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-	十		
		associated antigen p97," J. Natl. Cancer Inst. 81:445-448			
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	Τ		
	C63	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	T		
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434			
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296			
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326			
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749			
	C65	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108			
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, April 6-10, Abstract #2214			
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503			

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

1643



June 4, 2001

	FILING DATE	ART UNIT
(Use several sheets if necessary)	Srivastava et al.	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
	8449-178-999	09/873,403
	ATTY. DOCKET NO.	APPLICATION NO.

		NON PATENT LITERATURE DOCUMENTS			
Examiner					
Initials	C69	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly",	T		
	C09	Science 245:385-390	1		
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730	1-		
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and	+		
	0,.	chemotaxis", Immunology 50(2):251-9			
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New	<del> </del>		
	1	York p4			
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid			
		leukemia," Blood 96(4):1480-1489	1		
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-	1		
		55			
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae			
		provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4			
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae			
		multiplication in mouse footpads," Infect Immun. 62(10):4250-5			
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell			
		membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64			
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat			
		shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun.			
	<u> </u>	60(7):2565-71	—		
	C76	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum			
		protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	-		
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in			
	COL	Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	+-		
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	+		
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine			
	C83	B-cell leukemia/lymphoma" Clin. Can. Res.6:909  GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric	╁		
	Cos	focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476			
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines	+-		
	04	against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234			
· · · · · · · · · · · · · · · · · · ·	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North	+		
		America, Vol. 52:839-846			
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of	+-		
		Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120			
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites",	T		
		Science Vol. 250 113-116			
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and			
		endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-			
		16737.			
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	+-		
	109	IFACOW Ct at., 1700, Antibodics. A Labolatory Matitude Cit 0.137-243	1		

EXAMINER	DATE CONSIDERED
	MPED 600. Deep lies through sitation if not in conformation and not

Express Mail No.: ED 608 969 358 US

Sheet 6 of 6 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T		
milas	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera" Biochem, Mol. Biol. Int. 37(5):917-23			
- 100	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27			
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910			
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784			
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.			
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.			
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.			
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869			

EXAMINER	DATE CONSIDERED
·	





Express Mail No.: ED 608 969 358 US

Sheet 1 of 6 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE June 4, 2001 ART UNIT 1643

## REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

B25	WO 90/02564	3/22/90	Codon Dragon	
B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
B27	WO 92/01717	2/6/92	Burnie, James et al.	
B28	WO 92/08484	5/29/92	University College London	
B29	WO 92/08488	5/29/92	University College London	
B30	WO 93/14118	7/22/93	Medical Research Council	
B3	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
B33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
B34	WO 93/18150	9/16/93	Biocine S.P.A.	
B3:	WO 93/21529	10/28/93	Duke University	
B30	5 WO 93/24136	12/9/93	Terman, David S.	
B3*	7 WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
B3	WO 94/04676	3/3/94	The Victoria University of Manchester	
B3	WO 94/11513	5/26/94	Medical Research Council Colston	
B4	0 WO 94/14471	7/7/1994	Washington University	
B4	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
B4	2 WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
B4	3 WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
B4	A 0.75.75.75.74.75	2/27/97	Sloan-Kettering Institute for Cancer Research	
B4		2/27/97	Sloan-Kettering Institute for Cancer Research	
B4		03/20/97	Fordham University	
B4	7 WO 97/26910	7/31/97	Max-delbruck medizen milleck	
B4	8 WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
B4	9 WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
B5	0 WO 99/29834	06/17/99	Fordham University	

DATE CONSIDERED



Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE June 4, 2001 ART UNIT 1643

## FOREIGN PATENT DOCUMENTS

REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

 B25	WO 90/02564	3/22/90	Codon Dragon	
 B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
 	WO 92/01717	2/6/92	Burnie, James et al.	
 B27	WO 92/08484	5/29/92	University College London	
 B28				
B29	WO 92/08488	5/29/92	University College London	
B30	WO 93/14118	7/22/93	Medical Research Council	
B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
 B34	WO 93/18150	9/16/93	Biocine S.P.A.	
 B35	WO 93/21529	10/28/93	Duke University	
 B36	WO 93/24136	12/9/93	Terman, David S.	
B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
 B39	WO 94/11513	5/26/94	Medical Research Council Colston	
 B40	WO 94/14471	7/7/1994	Washington University	
 B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
 B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
B46	WO 97/10001	03/20/97	Fordham University	
B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
 B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
 B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
 B50	WO 99/29834	06/17/99	Fordham University	

<b>EXAMINER</b>
-----------------

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

•	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	
Examiner			
nitials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in	Γ
		patients with acute myocardial infarction. A comparison between streptokinase	
		and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	T
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC)	T
		Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"	ŀ
		American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a	T
		soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett.	
		1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress	Г
		protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	Γ
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa	T
		mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants	ľ
		and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by	Γ
		Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol.	
		98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the	
		mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl.	I
		Cancer Inst. <u>49</u> :493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by	
		methylcholanthrene", The Institute for Cancer Research 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic	
		reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a	
		partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol.	
		12(11):1539-46	L
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and	
		calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral	
		ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology	Т
		Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp.	Г
		17.1-17.12	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

LIST	<b>OF</b>	REFEREN	<b>ICES</b>	<b>CITED</b>	BY	APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	
FILING DATE June 4, 2001	art unit 1643

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)					
minais	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	Т		
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	T		
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171			
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36			
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502			
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356			
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23			
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs			
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8			
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147			
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415			
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288			
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679			
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860			
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227			
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324			
	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307			
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215			
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.			
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7			

#### **EXAMINER**

DATE CONSIDERED





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	
FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS		
Examiner nitials (Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)				
Initials	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	T	
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463		
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986		
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers		
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6		
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320		
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	T	
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208		
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673		
	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51		
	C61	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.		
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	Τ	
	C56	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448		
	C60	EVANS et al., 1999, Q.J. Med 92:299-307		
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	1	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434		
7	C61	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296		
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326		
	C65	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749		
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108		
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, April 6-10, Abstract #2214		
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503		

EXAMINER	DATE CONSIDERED
*FXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609: Draw line through citation if not in conformance and not





Sheet 5 of 6 of List of References

# LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	1
ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	
FILING DATE	ART UNIT
Tune 4 2001	1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
Initials	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390	-
<u></u>	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730	
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
diam.	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C79	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
3.4.4	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	

EXAMINER	DATE CONSIDERED





Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

LIST	OF	REFERE	ENCES	<b>CITED</b>	BY	APPL	<b>ICANT</b>

(Use several sheets if necessary)

ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
APPLICANT Srivastava et al.	
FILING DATE June 4, 2001	ART UNIT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T	
tilliais.	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera." Biochem. Mol. Biol. Int. 37(5):917-23		
- <del></del>	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27		
1 1117 17	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910		
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784		
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.		
	C96	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.		
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.		
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869		

DV A	MINER
LAA	WHITER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 1 of 6 of List of References

ATTY. DOCKET NO.	APPLICATION NO.
8449-178-999	09/873,403
APPLICANT	
Srivastava et al.	<del>-</del>
FILING DATE	ARTUNIT
June 4, 2001	1643

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

B25	WO 90/02564	3/22/90	Codon Dragon	
B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
B27	WO 92/01717	2/6/92	Burnie, James et al.	
B28	WO 92/08484	5/29/92	University College London	
B29	WO 92/08488	5/29/92	University College London	
B30	WO 93/14118	7/22/93	Medical Research Council	
B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
B33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
B34	WO 93/18150	9/16/93	Biocine S.P.A.	
B35	WO 93/21529	10/28/93	Duke University	
. Вза	WO 93/24136	12/9/93	Terman, David S.	
B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
B38	WO 94/11513	5/26/94	Medical Research Council Colston	
B40	WO 94/14471	7/7/1994	Washington University	-
B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
B41		2/13/97	The American National Red Cross – The General Hospital Corporation	
B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
B44	I Part of the state of the	2/27/97	Sloan-Kettering Institute for Cancer Research	
B4:		2/27/97	Sloan-Kettering Institute for Cancer Research	
B46	WO 97/10001	03/20/97	Fordham University	
B41	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
B50	WO 99/29834	06/17/99	Fordham University	

EXAMINE	ď
E-WANTED IN	

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403				
	APPLICANT Srivastava et al.				
	FILING DATE June 4, 2001	ART UNIT 1643			

•		NON PATENT LITERATURE DOCUMENTS	
xaminer		(Labella and of the such of (in CADITAL LETTERS) Title Date Portinent Pages Etc.)	Т
nitials	C08	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
· · · · · · · ·	C11	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"  American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	l
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
-	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", <i>The Institute for Cancer Research</i> 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
-	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not
considered. Include conv. of this form with next communication to applicant	

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 3 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999 09/873,403		
	APPLICANT Srivastava et al.		
			-
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials	,	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	
	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	L
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
=	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
· · · · · ·	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
- 1	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	T

	·
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in con-	nformance with MPEP 609; Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

Examiner		(1 1 1 CADITAL LETTERS) Tide Date Paris Base Fig.	T
nitials	C47	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)  CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	╁
			⊢
	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	L
	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	Ţ
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	T
-	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
-	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	Ī
-	C56	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C57	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	T
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	T
	C56	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	T
	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", <i>Nature</i> 348:248-251	Ī
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	Ì
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> 351:290-296	Ī
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	Ī
	C55	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	T
	C61	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	1
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	T

EV	ARA	IIN	ED	
EX	AΜ	IIN	ĸк	

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Bic.)  C69 FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390 C70 FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730 C71 FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9 C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4 C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489 C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55 C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4 G61. GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5 C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64 C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71 C90 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein form Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95 C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41 G81 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines			NON PATENT LITERATURE DOCUMENTS	
C69 FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390 C70 FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730 C71 FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9 C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4 C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489 C74 GAILUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55 C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4 C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5 C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64 C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71 C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(2):2387-95 C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41 C81 GRAHAM, et al. 1955, "Antibodies Ellicited by Cancer in Patients.", Cancer §:409-416 C82 GRANER et al., 2000, "Tumor-derived chaperone-rich cell Insates are effective therapeutic vaccines against a variety of cancers," Ca	xaminer		(Lab. da name of the cuthon (in CADITAL LETTERS) Title Date Partinent Pages Fits)	Т
Science 245:385-390 C70 FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730 C71 FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9 C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4 C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489 C74 GAILUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55 C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4 C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5 C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen. HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64 C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71 C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95 C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's abeta generation," J. Mol. Neurosci. 19:37-41 G81 GRAHAM, et al. 1995, "Anithbodies Elicited by Cancer in Patients.", Cancer 8:409-416 C82 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother, 49:476 C84 GRANER et al., 2003, "Timor-derived chaperone-rich cell lysates	iitiais	C60	IT VAIN at al. 1000 "Deptide hinding and release by proteins implicated as catalysts of protein assembly"	Ť
<ul> <li>C70 FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730</li> <li>C71 FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9</li> <li>C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4</li> <li>C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489</li> <li>C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55</li> <li>C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4</li> <li>C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5</li> <li>C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64</li> <li>C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71</li> <li>C79 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95</li> <li>C80 GOTO AND TANAIZ, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41</li> <li>C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416</li> <li>C82 GRANER et al. 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer</li></ul>		C69		1
C71 FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9  C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4  C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489  C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55  C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(3):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C84 GRANER et al., 2000, "Immunoprotective activities of multiple chaperone activities of multiple chaperone." Surgical Clinics of North America		670	Science 243:383-390	╁
chemotaxis". Immunology 50(2):251-9  C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4  C73 GAIGER et al., 2000. "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489  C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55  C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al., 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived chaperone-erich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C84 GRANER et al., 2003, "Fumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a var			FLYNN et al., 1991, "Peptide-binding Specificity of the Wolecular Chapetone Bir", Wature 353,720-750	╁
C72 FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4 C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489 C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55 C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4 C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5 C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64 C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71 C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95 C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41 C81 GRAHAM, et al., 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416 C82 GRANER et al., 2000, "Tumor-derived multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909 C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476 C84 GRANER et al., 2000, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234 GROBMANN et al.,		C/1		
York p4  C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489  C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55  C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice." Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation." J. Mol. Neurosci. 19:37-41  C81 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemial/ymphoma" Clin. Can. Res.6:909  C83 GRANER et al. 2000, "Immunoproterived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2000, "Tumor-derived dhaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Ir., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  G86 GROBMANN et al., 1997, "Active-Specific Im		1072	Chemotaxis, immunology 50(2):251-9	╁╴
C73 GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489  C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55  C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemiallymphomas" Clin. Can. Res. 6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics o		C/2		
leukemia," Blood 96(4):1480-1489  C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55  C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton artigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al., 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone errichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived multiple chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America. Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunothera		072	YORK P4	╁
C74 GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55 C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4 C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5 C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64 C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71 C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95 C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41 C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416 C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemial/ymphoma" Clin. Can. Res.6:909 C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:26-234 C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunothers. 52(4):226-234 C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas in Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120 C87 HALEVY et al., 1996, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-ma		C/3		
C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al., 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:4716  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Panceatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY e		C	leukemia," Blood 96(4):1480-1489	+
C75 GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C79 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunotopic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherrapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY e		C74		
provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4  C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers." Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunotopic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 2		-		-
C76 GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated		C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae	
multiplication in mouse footpads," Infect Immun. 62(10):4250-5  C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem.				+
<ul> <li>C77 GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64</li> <li>C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71</li> <li>C79 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95</li> <li>C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation." J. Mol. Neurosci. 19:37-41</li> <li>C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416</li> <li>C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemiallymphoma" Clin. Can. Res.6:909</li> <li>C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476</li> <li>C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234</li> <li>C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846</li> <li>C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas in Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120</li> <li>C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116</li> <li>C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin bindin</li></ul>		C76		
membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64  C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation." J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		ļ	multiplication in mouse footpads," Infect Immun. 62(10):4250-5	+-
C78 GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C79 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell	
shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	╀
60(7):2565-71  C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat	1
C77 GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rimmunol. Immunother. 49:476  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.				
protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95  C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			60(7):2565-71	╀
C80 GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer §:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C77	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum	
Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41  C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		1	protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	_
C81 GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416  C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C80		1
C82 GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	1
B-cell leukemia/lymphoma" Clin. Can. Res.6:909  C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C81	GRAHAM, et al. 1955, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	$\bot$
C83 GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine	1
focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476  C84 GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			B-cell leukemia/lymphoma" Clin. Can. Res.6:909	┸
GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric	
against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234  C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	$\perp$
C85 GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines	
America, Vol. 52:839-846  C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
C86 GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North	
Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120  C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			America, Vol. 52:839-846	
C87 HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of	
Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites",	
C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.			Science Vol. 250 113-116	
endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.		C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and	
16737.			endocytic vesicles inhibit alpha2-macroglobulin binding and uptake". J. of Biol. Chem. 261(35): 16732-	
				+

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	$ _{\mathbf{T}}$		
	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera," Biochem. Mol. Biol. Int. 37(5):917-23			
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27			
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910			
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784			
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.			
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.			
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.			
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869			

EXAMINER	DATE CONSIDERED

11-13-07



Express Mail No.: *ED 608 969 344 US* 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava et al.

Confirmation No.: 1802

Application No.: 09/873,403

Art Unit: 1643

Filed: June 4, 2001

Examiner: Christopher H. Yaen

For:

COMPLEXES OF ALPHA (2)

Attorney Docket No:

8449-178-999

MACROGLOBULIN AND ANTIGENIC MOLECULES FOR IMMUNOTHERAPY

(CAM No:

708584-999177)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97

MAIL STOP RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 COPY

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references A01-A56, B01-B50, and C08 to C283 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references A01, B01-B50 and C08-C283 are enclosed herewith. Copies of references A02-A56 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (see Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. §1.98(a)(3)(i), a concise explanation of the relevance of non-English documents (references B01 and B47) is provided herewith. The relevance of reference B01, German Patent DE 19602985, can be explained by the English translation of

sheet 2 of 2 Attorney Docket No.: 8449-178-999 Application No.: 09/873,403 Applicant: Srivastava

the abstract: Tumor vaccine, for immune therapy of tumors, comprises tumor cells which also contain a gene for an exogenic heat shock protein. The relevance of reference B47, PCT Application No. WO 97/26910, can be explained by the English translation of the abstract:

The invention concerns a tumor vaccine in which the immunogenicity of tumor cells, tumor associated antigens or antigen partial structures are reinforced through genetic modification or through chemical bonding to an exogenous thermal shock protein. The use of microbial thermal shock proteins or their genes is preferred which are derived from mycobacteria, Escherichia coli or from Chlamydia trachomatis.

While not to be construed as indicating that the Examiner should not review and consider fully all the listed references, Attorneys for Applicant particularly direct the Examiner's attention to references A05, A08, A11, C177-C181, and C184-C186.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97 (b)(4), Applicants believe that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if the Patent Office determines otherwise, the Commissioner is authorized to charge any required fees to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date: November 8, 2007

Adriane M. Antler

(Reg. No.)

**JONES DAY** 

222 East 41st Street

New York, New York 10017

Phone: (212) 326-3939



REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

COPY

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 1 of 3 of List of References

ATTY. DOCKET NO. 8449-178-999

APPLICATION NO. 09/873,403

APPLICANT

Srivastava et al.

FILING DATE
June 4, 2001

ART UNIT

1643

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
2111112	A01	09/393,652	9/10/99	Srivastava	
	A02	2001-0034042	10/01	Srivastava	
	A03	2002-0001841	1/03/02	Kaltoft et al.	
	A04	2002-0028207	6/4/01	Srivastava	
	A05	2002-0037290	03/28/02	Armen	
	A06	2002-0172682	11/21/02	Srivastava	
	A07	2002-0192230	12/19/02	Srivastava	
_ ,	A08	2003-0129296	07/10/03	Srivastava	
	A09	2003-0211971	11/13/03	Srivastava	
	A10	2004-0022796	02/05/04	Srivastava	
	All	2004-0253228	12/16/04	Srivastava	
	A12	2006-0165710	07/26/06	Srivastava	
	A13	4,690,915	9/1/87	Rosenberg	
	A14	5,112,298	5/12/1992	Prince et al.	
	A15	5,188,964	2/23/93	McGuire et al.	
	A16	5,232,833	8/3/93	Sanders et al.	
	A17	5,273,965	12/28/93	Kensil et al.	
-1.	A18	5,348,945	9/20/94	Berberian et al.	
	A19	5,554,293	9/10/1996	Uhoch	
	A20	5,580,859	12/3/96	Felgner et al.	
	A21	5,637,082	6/10/1997	Pages et al.	
-	A22	5,652,115	7/29/97	Marks et al.	
	A23	5,736,146	4/7/98	Cohen	
	A23	5,747,332	5/5/98	Wallen et al	
	A25	5,750,119	05/12/98	Srivastava	
	A26	5,830,464	11/03/98	Srivastava et al.	
	A27	5,846,928	12/8/1998	Kishida	
	A28	5,869,058	2/9/99	Cohen	
	A29	5,891,653	4/6/99	Attfield	
	A30	5,910,306	06/99	Alving et al.	

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u>

Sheet 2 of 3 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	8449-178-999	09/873,403	
	APPLICANT		
	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4 2001	1643	

*EXAMINER	<u> </u>				PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT
INITIAL	A31	5,947,646	07/19/99	NAME Srivastava et al.	FIGURES APPEAR
	A31	5,968,526	10/19/99	Garman et al.	
		5,997,873	12/7/99	Srivastava et al.	
	A33	6,007,821	12/28/99	Srivastava et al.	
		6,027,731	2/22/2000	Pauza	
	A35	6,030,618	02/29/00	Srivastava	
	A36	6,033,561	3/7/2000	Schoendorfer	
	A37	6,048,530	4/11/00	Srivastava	
	A38	6,136,315	10/24/00	Srivastava	
	A39				
	A40	6,156,311	12/05/00	Strickland et al. Srivastava	
	A41	6,162,436	1/2/01	Srivastava et al.	
	A42	6,168,793			
	A43	6,312,711	11/6/01	Duchateau et al.	
	A41	6,333,311	12/25/2001	Nuijens et al.	
	A45	6,338,945	01/15/02	Nicolette	
	A46	6,403,092	6/11/02	Pizzo et al.	
	A47	6,433,141	8/13/02	Wallen et al.	
	A48	6,689,363	02/10/04	Sette et al.	
	A49	6,709,672	3/23/04	Henot et al.	
	A50	6,713,608	3/30/04	Wallen et al.	
	A51	6,730,302	5/4/04	Fujihara et al.	
	A52	6,797,480	9/28/04	Srivastava	
	A53	6,986,389	01/06	Li	
	A54	7,176,515	03/06/07	Srivastava et al.	
	A55	7,179,462	02/20/07	Srivastava et al.	
	A56	7,132,109	11/07/06	Srivastava	

EVAN	1INER
L AAIV	INCR

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 344 US</u> Sheet 3 of 3 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403			
	APPLICANT Srivastava et al.			
	FILING DATE June 4, 2001	ART UNIT 1643		

B01	DE 196 02 985 A1	1/27/96	Germany	
	GB 2 251 186A	7/1/92	United Kingdom	
B02				
B03	WO 00/03003	1/20/00	University of Nottingham	
B04	WO 00/10597	03/02/00	Immunology Limited	
B05	WO 00/34494	6/15/00	The Government of the United States of America represented by the Secretary, Dept. of Health and Human Services	
B06	WO 00/38760	7/6/2000	Occulogix Corp	
B07	WO 00/46246	8/10/00	The General Hospital Corp.	
B08	WO 00/54801	9/21/2000	Entremed Inc	
B09	WO 01/91787	6/12/01	University of Conneticut Health Center	
B10	WO 01/92474	12/06/01	University of Conneticut Health Center	
B11	WO 02/07755	1/3/2002	The General Hospital Corporation	
B12	WO 02/11669	02/14/02	Antigenics, LLC	
B13	WO 02/15930	2/28/02	Duke University	
B14	WO 02/30434	4/18/02	University of Conneticut Health Center	
B15	WO 02/32923	4/25/02	University of Conneticut Health Center	
B16	WO 02/34205	5/2/02	University of Conneticut Health Center	
B17	WO 03/015712	02/27/03	University of Conneticut Health Center	
B18	WO 03/090686	11/06/03	University of Conneticut Health Center	
B19	WO 03/092624	11/13/03	University of Conneticut Health Center	
B20	WO 04/035602	04/29/04	University of Conneticut Health Center University of Conneticut Health	
B21	WO 04/075636	09/10/04	Center University of Conneticut Health University of Conneticut Health	
B22	WO 04/74454	09/02/04	Center University of Conneticut Health University of Conneticut Health	
B23	WO 05/120558		Center	<u> </u>
B24	WO 89/12455	12/28/89	Whitehead Institute for Biomedical Research Medical Research Council	

EXAMINER	DATE CONSIDERED
----------	-----------------

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403			
	APPLICANT Srivastava et al.			
	FILING DATE June 4, 2001	ART UNIT 1643		

		FOREIGN	N PATENT DOCUMENTS	
B25	WO 90/02564	3/22/90	Codon Dragon	
B26	WO 91/15572	10/17/91	The Wellcome Foundation Limited	
B27	WO 92/01717	2/6/92	Burnie, James et al.	
B28	WO 92/08484	5/29/92	University College London	
B29	WO 92/08488	5/29/92	University College London	
B30	WO 93/14118	7/22/93	Medical Research Council	
B31	WO 93/17712	9/16/93	Biocine Sclavo Spa Rappuoli	
B32	WO 93/18146	9/16/93	Institut National de la Sante et de la researche medicale	
В33	WO 93/18147	9/16/93	Institute Nazionale per lo studio e la cura dei tumori fondazione giovanni pascale	
B34	WO 93/18150	9/16/93	Biocine S.P.A.	
B35	WO 93/21529	10/28/93	Duke University	
B36	WO 93/24136	12/9/93	Terman, David S.	
B37	WO 94/03208	2/17/94	Yeda Research and Development Company, Ltd	
B38	WO 94/04676	3/3/94	The Victoria University of Manchester	
B39	WO 94/11513	5/26/94	Medical Research Council Colston	
B40	WO 94/14471	7/7/1994	Washington University	
B41	WO 94/29459	12/22/94	Whitehead Institute for Biomedical Research	
B42	WO 97/04794	2/13/97	The American National Red Cross – The General Hospital Corporation	
B43	WO 97/06685	2/27/97	Sloan-Kettering Institute for Cancer Research	
B44	WO 97/06821	2/27/97	Sloan-Kettering Institute for Cancer Research	
B45	WO 97/06828	2/27/97	Sloan-Kettering Institute for Cancer Research	
B46	WO 97/10001	03/20/97	Fordham University	
B47	WO 97/26910	7/31/97	Max-delbruck medizen milleck	
B48	WO 98/42752	10/01/98	Brigham and Woman's Hospital Inc.	
B49	WO 98/46739	7/23/97	Juridicial Foundation the Chemo-Sero- therapeutic Research Institute	
B50	WO 99/29834	06/17/99	Fordham University	

TOVA	MI	NER
P.AA	IVII	INP.K

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 2 of 6 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. APPLICATION NO. 8449-178-999 09/873,403			
	APPLICANT Srivastava et al.			
	FILING DATE June 4, 2001	ART UNIT 1643		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C08	ABBAS et al., 1991, Cellular and Molecular Immunology, W.B. Saunders Co., Philadelphia (Chapters 15-18)	
	C09	AGOSTONI et al., 1994, "Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator." Circulation. 90(6):2666-70.	
	C10	ALDOVINI et al., 1992, "The New Vaccines", Technology Review pp. 24-31	
	CII	AMATO et al., 1999, "Active Specific Immunotherapy in Patients with Renal Cell Carcinoma (RCC) Using Autologous Tumor Derived Heat Shock Protein-Peptide Complex-96 (HSPP-96) Vaccine"  American Society Clinical Oncology Meeting, abstract 1278	
	C12	ANDERSEN, P. 1994, "Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins," Infect. Immun. 62(6):2536-44	
	C13	ANDUS et al., Synthesis of alpha 2-macroglobulin in rat hepatocytes and in a cell-free system. FEBS Lett. 1983 Jan 10;151(1):10-14	
•	C14	ANTHONY et al., 1999, "Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule," Vaccine 17(4):373-83	
	C15	BANCHEREAU et al., 1998, "Dendritic cells and the control of immunity," Nature 392:245-252	
	C16	BARRIOS et al., 1992, "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and BacillusCalmette Guerin priming," Eur. J. Immunol. 22(6):1365-72	
	C17	BARRIOS et al., 1994, "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and Dna K proteins requires cross-linking with antigen," Clin. Exp. Immunol. 98(2):229-233	
	C18	BARRIOS et al., 1994, "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol. 98(2):224-8	
	C19	BARTLETT, 1972 "Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors." J. Natl. Cancer Inst. 49:493-504	
	C20	BASOMBRÍO (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", The Institute for Cancer Research 30:2458-2462	
	C21	BASU and SRIVASTAVA, 1999, "Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity" J. Exp. Med. 189:797-802	
, , , , ,	C22	BASU et al., 2000, "Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway," Int. Immunol. 12(11):1539-46	
	C23	BASU et al., 2001, "CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin," Immunity 14:303-313	
	C24	BEDNAR et al., 1997, "Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke." J. Neurosurg. 86(1):139-42.	
	C25	BELLONE et al., 1999, "Cancer Immunotherapy: synthetic and natural peptides in balance," Immunology Today 20(10): 457-462	
	C26	BEVERLY, 1988, "Tumour Immunology." In: <i>Immunology</i> , 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12	

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformation considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not	ı

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	09/8/3,403
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	T	(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C27	BINDER and Srivastava, 2004, "Essential role of CD91 in re-presentation of gp96-chaperoned peptides," Proc. Natl. Acad. Sci. U.S.A. 101:6128-6133	
	C28	BINDER et al., 2000, "CD91: a receptor for heat shock protein gp96," Nature Immunol. 1(2):151-155	1
ð	C29	BINDER et al., 2001, "Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatability complex I molecules," J. Biol. Chem. 276(20): 17163-17171	
-	C30	BIRKENMEIER G., 2001, "Targetting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin." Mod. Asp. Immunobiol. 2(1):32-36	
	C31	BLACHERE and SRIVASTAVA (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells", J. Cellular Biochem. Keystone Symposia, 17D: pp. 124, Abstract NZ 502	
W. *****	C32	BLACHERE et al., 1993, "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356	
	C33	BLANDER et al., 1993, "Major cytoplasmic membrane protein of Legionella pnumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease," J. Clin. Invest. 91(2):717-23	
	C34	BODEY et al., 2000, Anticancer Res 20:2665-2676 Abs	$oxed{oxed}$
	C35	BOSCH et al., 1999, "State of the art of therapeutic apheresis in Europe", Ther. Apher. 3(3):197-8	
	C36	BRELOER et al., 1999, "in vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins," J. Immunol. 162:3141-3147	
	C37	BUMOL et al., 1988 "Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody." Hybridoma 7:407-415	
	C38	CARSWELL et al., 1970, "Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice." Natl. Cancer Inst. 44:1281-1288	
	C39	CASSEL et al., 1977, "Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses," Cancer 40:672-679	
	C40	CASSEL et al., 1983 "A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate." Cancer, 52:856-860	
	C41	CASTELLI et al., 2001, "Human Heat Shock Protein 70 Peptide Complexes Specifically Active Antimelanoma T cells." Cancer Res 61:222-227	
	C42	CHANDAWARKAR et al., 2004, "Immune modulation with high-dose heat shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis," Int'l. Immunol. 16:315-324	
	C43	CHU et al., 1994, α <sub>2</sub> -Macroglobulin: A Sensor for Proteolysis," Ann. N.Y. Acad. Sci. 737:291-307	Τ
	C44	CLARKE et al. 1988, "Purification of Complexes of Nuclear Oncogene p53 with Rat and Escherichia coli Heat Shock Proteins: In Vitro Dissociation of hsc70 and dnaK from Murine p53 by ATP" Mol. and Cell. Biol. Vol. 8 (3) 1206-1215	
	C45	COLLEN et al., 1989, "Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent." Drugs. 38(3):346-88.	
	C46	COSTANZO, 1996, "New monoclonal antibodies," Curr. Opin. Cardiol. 11(2):204-7	1

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 4 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т
	C47	CRAIG, 1993, "Chaperones: Helpers Along the Pathways to Protein Folding," Science 260:1902-4	
. 10.4	C48	D'ANDREA, 2005, "Add Alzheimer's disease to the list of autoimmune diseases," Med. Hypotheses 64(3):458-463	
,,,,,	C49	DASH, et al., 2002 "Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor." J. Biol. Chem. 277:17978-17986	
	C50	DAVIDOFF et al., 1992, "Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers	
	C51	DEL GIUDICE et al., 1994, "Hsp70: a carrier molecule with built-in adjuvanticity", Experientia 30;50(11-12):1061-6	
	C52	DERMER, 1994, "Another Anniversary for the War on Cancer," Biotechnology 12:320	
	C53	DEUTSCHER et al., 1992 "Guide to protein purification." Meth. Enzymol., 182:610-611	
	C54	DUBOIS et al., 1980, "Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells," Cancer Res. 40:4204-4208	
	C55	DUBOIS, et al., 1982 "Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas." Proc. Natl. Acad. Sci USA, 79:7669-7673	
	C59	ELLGAARD ET AL., 1997,"Dissection of the domain architecture of the alpha2macrglobulin-receptor associated protein." Eur. J. Biochem 244:544-51	
	C59	EPPLEN et al., 1997, "Genetic predisposition to multiple sclerosis as revealed by immunoprinting," Ann. Neurol. 41(3):341-52.	
	C58	ESPANA et al., 1996, Clin. Chem 42(3):545-550	
	C59	ESTIN et al., 1989, "Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97," J. Natl. Cancer Inst. 81:445-448	
	C60	EVANS et al., 1999, Q.J. Med 92:299-307	
<del></del>	C61	FALK et al., 1990, "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules". <i>Nature</i> 348:248-251	
	C62	FALK et al., 1991, "Identification of Naturally Processed Viral Nonapeptides Allows Their Quantification in Infected Cells and Suggests an Allele-specific T Cell Epitope Forecast". J Exp. Med 174:425-434	Ī
	C63	FALK et al., 1991, "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", <i>Nature</i> 351:290-296	Ī
	C64	FALK et al., 1992, "Specificity of antigen processing for MHC class I restricted presentation is conserved between mouse and man", Eur. J. Immunol. 22:1323-1326	
	C§5	FAY et al., 1979, "Leukopheresis Therapy of Leukemic Reticuloendotheliosis (Hairy Cell Leukemia)", Blood 54: 747-749	
	C66	FEDWEG and SRIVASTAVA "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School of Medicine NZ 206, p. 108	
	C67	FENG et al., 2002, "Exogenous heat shock proteins provide adjuvant effects on enhancing the immunogenicity of apoptotic tumor cells and inducing antitumor immunity," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, April 6-10, Abstract #2214	
	C68	FERRERO et al., 1995, The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92(14):6499-503	

EXAMINER	
----------	--

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 5 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	1
- Intidio	C69	FLYNN et al., 1989, "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390	
	C70	FLYNN et al., 1991, "Peptide-binding Specificity of the Molecular Chaperone BiP", <i>Nature</i> 353:726-730	T
	C71	FORRESTER et al., 1983, "Effect of modified alpha 2macroglobulin on leucocyte locomotion and chemotaxis", Immunology 50(2):251-9	
, ,,,,,	C72	FRESHNEY, 1983, "Culture of Animal Cells, A Manual of Basic Technique," Alan R. Liss Inc., New York p4	
	C73	GAIGER et al., 2000, "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," Blood 96(4):1480-1489	
	C74	GALLUCCI et al., 1999, "Natural adjuvants: endogenous activators of dendritic cells," Nat. Med. 5:1249-55	
	C75	GELBER et al., 1992, "Vaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection," Infect Immun. 60(5):1840-4	
	C76	GELBER et al., 1994, "Vaccination with pure Mycobacterium leprae proteins inhibits M. leprae multiplication in mouse footpads," Infect Immun. 62(10):4250-5	
	C77	GOMEZ et al., 1991, "Protective efficacy of a 62-kilodalton antigen, HIS-62, from the cell wall and cell membrane of Histoplasma capsulatum yeast cells." Infect Immun. 59(12):4459-64	
	C78	GOMEZ et al., 1992, "An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice," Infect Immun. 60(7):2565-71	
	C76	GOMEZ et al., 1995, "Vaccination with recombinant heat shock protein 60 from Histoplasma capsulatum protects mice against pulmonary histoplasmosis." Infect Immun. 63(7):2587-95	
	C80	GOTO AND TANZI, 2002, "The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's Abeta generation," J. Mol. Neurosci. 19:37-41	
	C81	GRAHAM, et al. 1955,, "Antibodies Elicited by Cancer in Patients.", Cancer 8:409-416	
	C82	GRANER et al. 2000, "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma" Clin. Can. Res.6:909	
	C83	GRANER et al., 2000, "Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines" Cancer Immunol. Immunother. 49:476	
	C84	GRANER et al., 2003, "Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers," Cancer Immunol. Immunother. 52(4):226-234	
	C85	GRIFFEN, Jr., et al. 1972, "Colon Carcinoma and Immunologic Phenomena." Surgical Clinics of North America, Vol. 52:839-846	
	C86	GROBMANN et al., 1997, "Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines." Anticancer Res. 17: 3117-3120	
	C87	HALEVY et al. 1990, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activites", Science Vol. 250 113-116	
	C88	HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.	
	C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	7

C89 HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243	Science Vol. 250 113-116  C88 HANOVER et al., 1986, "Monoclonal antibodies against a glycoprotein localized in coated pits and endocytic vesicles inhibit alpha2-macroglobulin binding and uptake", J. of Biol. Chem. 261(35): 16732-16737.				
DATE CONSIDERED		C89	HARLOW et al., 1988, "Antibodies: A Laboratory Manual" ch 6:139-243		
EAAMINER	EXAMINE	R	DATE CONSIDERED		

Express Mail No.: <u>ED 608 969 358 US</u> Sheet 6 of 6 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	1037010,100
	FILING DATE June 4, 2001	ART UNIT 1643

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	Т	
	C90	HEEB et al., 1995, "Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera," Biochem. Mol. Biol. Int. 37(5):917-23		
	C91	HEISKALA et al., 1988 "Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity." Scand. J. Immunol. 28:19-27		
	C92	HENTTU AND VIHKO, 1989 "cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes." Biochem. Biophys. Res. Comm. 160:903-910		
	C93	HERZ AND STRICKLAND, 2001, "LRP: a multifunctional scavenger and signaling receptor," J. Clin. Invest. 108:779-784		
	C94	HERZ et al., 1990, "Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver", J. of Biol. Chem. 265(34): 21355-21362.		
	C95	HERZ et al., 1991, "39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor." J.Biol.Chem. 266(31):21232-21238.		
	C96	HEY et al., 1988, "Cloning of a novel member of the low-density lipoprotein receptor family", Gene 216: 103-111.		
	C97	HINDS et al., 1987, "Immunological Evidence for the Association of p53 with a Heat Shock Protein, hsc70, in p53-plus-ras-Transformed Cell Lines" Mol. and Cell. Biol. Vol.7 (8) 2863-2869		

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS	
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580	
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)	
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.	
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4	
C102	HOUGHTEN et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86	
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8	
C104		
	HUGHES et al., 1981, "Characterization of plasma membrane proteins identified by monoclonal antibodies", J. of Biol./ Chem. 256(2): 664-671.	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305	
C107		
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.	
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9	
C110		
C111		
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520	
. C113		-
C114		
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V. Sections 13-1 to 13-15)	
C116		•
C117		
C118		

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet **2** of **9** of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	09/8/3,403	
	FILING DATE June 4, 2001	art unit 1643	

	NON PATENT LITERATURE DOCUMENTS
C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, Abstract #5516
C124	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	KOO, 1982, "Characterization of growth-inhibitory activities associated with an alpha-macroglobulin of mice." Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	53:1333-1336
	KRISTENSEN et al., 1990, "Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
C130	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Pentides across the ER Membrane". Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
C136	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	

	C139	MADDEN et al., 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", Nature 353:321-325
EXA	MINER	DATE CONSIDERED
*EXA	MINER: Initia	al if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	09/073,403
	FILING DATE June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS
C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University
C141	
C142	
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression", Nat. Med. 5:581-7
C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General", Career Surveys 13:81-99
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American Society for Microbiology pp. 1-13
C146	idea whose time has come" Semin. in Oncology 25:654
C147	constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C149	Clin. Apheresis 1: 25-32
C149	Biotherapy 10:173-185
C150	MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	
C154	Recombinant Interleukin-2", Science 225:1487-1489
C155	MUNRO et al., 1986, "An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	MURRAY et al., 1977 "Viral Oncolysate in the Management of Malignant Melanoma II, Clinical Studies." Cancer 40:680-686
C157	NAIR et al., 1977 "Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	NAIR et al., 1999, "Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides" <i>J. Immunol.</i> 162:6426
C159	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether	or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

	NON PATENT LITERATURE DOCUMENTS	
C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the	
	stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	—
C161	NORRBY, 1985, "Summary," in: <i>Vaccines 85</i> , Lerner <i>et al.</i> , eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY pp. 387-394	1
C162		<del>- </del>
1 102	Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	l
C163		
C164		
C165		
C166		
C167		
C168		
C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00	
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	
C171		
C172	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00	
C173	OFFICE ACTION mailed on 09/21/06 for U.S. Application No. 09/668,724 filed 09/22/00	
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00	
C175		
C176	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00	
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02	
C179	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C186	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	-
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	1
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	
C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05	
C184	OFFICE ACTION mailed on 02/22/07 for U.S. Application No. 10/784,012 filed 02/20/04	
C185		
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	1
C187	recentor-4 complex. J. Immunol. 164:558-561	
C188		
C189		
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis." Infect Immun. 60(11):4781-92	

#### EXAMINER

DATE CONSIDERED .

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLtCANT	
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

1 610	International tour was a second of the secon
	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", Cancer Research 47:5074-5079
C19	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62
C19	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189- 220 Cited On pp.1173-1174
C19	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
C19	6 PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No. PCT/US03/14390
	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No. PCT/US01/23098
	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No. PCT/US01/18041
C19	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No. PCT/US02/26573
	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C20	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C20	
C20	7 PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst. 18:769-778
C20	
C20	P RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54
C21	
C21	
C21	
C21	

	EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance an considered, the lude copy of this form with next communication to applicant			

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

Lon	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related
C21	
C21	Processes in Cells", Cell 59:591-601  RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized
C21	
	by Cytotoxic T cells", <i>Nature</i> 348:248-251 ROTZSCHKE, 1990, "Characterization of Naturally Occurring Minor Histocompatibility Peptides
C21	ROIZSCHKE, 1990, "Characterization of Naturally Occurring without Histocompationity Teptides
	including H-4 and H-Y" Science 249: 283-287  SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C21	
C21	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by
	maintained by granulocyte/macrophage colony-stitutiating factor plus interleukin 4 and downlegulated by
C21	tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118  SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide
C21	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-
	reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
Gaa	
C22	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med.
C22	191:423-434   SCHREIBER, 1989 "Tumor Immunology." In: Fundamental Immunology, 2nd Edition, Paul, ed., pp;
C22	
COO	923-955 2 SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706
C22	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on
C22	HLA Class I and Class II," J. Immunol. 173:1987-1993
C22	
C22	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C22	
C22	43:79-94
C22	
C22	Carcinoma Patients." Scand J. Immunol 33:699-706
C22	
C22	hsp90", J. Mol. Biol. 194(2):341-4
C22	
C22	Acta. Neurol. Scand. 98(5):314-7
C22	
C22	111:1057-1062
C23	
	Surgical Procedures," 19-22
C23	
	Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
- 1023	2 SRIVASTAVA and OLD (1989) "Gp96 Molecules: Recognition Elements in Tumor Immunity", Human
(22)	Tumor Antigens and Specific Tumor Therapy, pages 63-71
C23	
(22)	Curr. Opin. Immunol. 6:728
C23	
[ 223	Immunity:, Cellular Immunity and the Immunotherapy of Cancer, pages 307-314

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS
С	-	is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
С	236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors," Proc. Natl. Acad. Sci USA 84(11):3807-3811
С		SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse tumors," Immunol. Today 9:78-83
	1	SRIVASTAVA et al., 1989, "Identification of a Human Homologue of the Murine Tumor Rejection Antigen GP96," Cancer Res. 49:1341-1343
C	239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
C		protein GP96: Implications for vaccination against cancer and infectious diseases", <i>J Cell Biochem Suppl</i> 17D:94 (Abstract NZ014)
C		SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world", Immunity 8(6):657-65
C		SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm", Experientia. (11-12):1054-60
C	243	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C	244	SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev. Immunol. 2(3): 185-194
C	245	STACK et al., 1982, "Autologous x-irradiated tumour cells and percutaneous BCG in operable lung cancer," Thorax 37(8):588-593
С	246	STEINMAN, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C	247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C	248	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8 Review
C	249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57
C	250	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
	251	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in: Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.), Birkhauser/Springer, 77: 451-465
C	252	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1" p24. J Immunol. 156(2):873-9
C	253	TAILOR et al., 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
C	254	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
C	255	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	mance with MPEP 609; Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.	

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS
	C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
		Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
	C257	TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines
		and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
	C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast
tissue," Mol. Cell. Biochem. 18(2-3):101-7		
	C259	UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96,
		hsp90, and hsp70," J. Immunol., 152(11):5398-5403
	C260	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the
		tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
	C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein,"
		Proc. Natl. Acad. Sci. USA 83(10):3121-3125
	C262	URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ
		300(6725):662-5 Review
	C264	VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res.
		<u>28</u> :2477-2483
	C264	VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of
	0.00	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
	C265	VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse
		b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
	C266	WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility
		complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
	C267	WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as
		cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
		497
	C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of
		ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
	C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
	C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
	C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem.
		257:14949-14959
	C272	WELCH et al., 1985, "Rapid Purification of Mammalian 70,000-Dalton Stress Proteins: Affinity of the
		Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
	C273	WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes
		in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
		fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
	C274	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
	C275	WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin
		in vivo and in vitro." The Biochemical Journal. England 313:71-76
	C276	
		on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
	C277	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment
		of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.	
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540	
C280	an experimental prostate cancer model" Int. J. Mol. Med. 3:243	
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627	
C282		
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.	

EXAMINER	DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

box 3 of 3

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

ATTY. DOCKET NO.

8449-178-999

APPLICANT

Srivastava et al.

Filing date

June 4, 2001

APPLICATION NO.

09/873,403

ART UNIT

1643

### F REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
 C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
 C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
 C102	HOUGHTEN et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86
 C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8
C104	
 C105	
 C106	
C107	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	ISRAELI et al., 1993, "Molecular Cloning Of A Complementary DNA Encoding A Prostate-Specific Membrane Antigen." Cancer Res. 53:227-230
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
 C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
	JAMES, K., 1980, "Alpha (2) macroglobulin and its possible importance in immune systems," Trends in Biol. Sci. p.43-47
	JANETZKI et al., 2000, "Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study" Int. J. of Cancer 88:232-238
	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	JOCHAM et al., 2004, "Adjuvant Autologous Renal Tumour Cell Vaccine and Risk of Tumour Progression in Patients with Renal-Cell Carcinoma After Radical Nephrectomy: Phase III, Randomised Controlled Trial." The Lancet, Vol 363:594-599

EXAMINER

NOV 0 8 2007

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

	NON PATENT LITERATURE DOCUMENTS
C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	
C121	hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	transduced tumor cells in the control of LLC tumor," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, Abstract #5516
C124	KOL et al., 2000, "Cutting edge: heat shock protein (HSP)60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	mice," Cancer Res. 42(5):1788-97
C126	<u> </u>
C127	53:1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
C130	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
C132	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	LIVINGSTON et al. 1985, "Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C135	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	
C139	

EXAMINER	DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research
	46:2189-2192
C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997
C143	<u> </u>
	induction of heat shock protein expression", Nat. Med. 5:581-7
C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication
0145	in General", Career Surveys 13:81-99
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American Society for Microbiology pp. 1-13
C146	MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
	MILLWARD AND HOELTGE, 1982, "The Historical Development of Automated Hemapheresis", J. of Clin. Apheresis 1: 25-32
C147	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer," Biotherapy 10:173-185
C150	
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	MULÉ et al., 1984, "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2", Science 225:1487-1489
C155	<del>}</del>
C156	
C157	
C158	
C159	

	EXAMINER	DATE CONSIDERED	
ſ	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and neconsidered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the	
stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139		
C161	NORRBY, 1985, "Summary," in: Vaccines 85, Lerner et al., eds., Cold Spring Harbor Laboratory, Cold	
	Spring Harbor, NY pp. 387-394	
C162	OETTGEN AND OLD, 1991 "The History Of Cancer Immunotherapy." In: Introduction To The Biologic	
	Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	
C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00	
	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	
C165	OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00	
	OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00	
C167	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00	
C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	
C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00	
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	
C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00	
	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00	
C179		
C174	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00	
C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	
	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00	
C177	<u> </u>	
C179	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02	
C179	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	
C183		
C184		
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	
C187		
C188	receptor-4 complex. J. Immunol. 164:558-561  OLD et al., 1962 "Part II. Antigens Of Tumor Cells. Antigenic Properties Of Chemically-Induced	
C166	Tumors." Ann. N.Y. Acad. Sci. 101:80-106	
C189		
	Aliment Pharmacol Ther. 13(1):35-42.	
C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces	
	cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary	

## EXAMINER DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

		NON PATENT LITERATURE DOCUMENTS	
	C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced	
	BALB/c sarcomas", Cancer Research 47:5074-5079		
	C192	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62	
,	C193	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity	
i		Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and	
		Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204	
	C194		
		220 Cited On pp.1173-1174	
	C195	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY	
		PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No.	
		PCT/US03/14390	
	C197	<u> </u>	
		PCT/US01/23098	
	C198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No.	
		PCT/US01/18041	
	C199	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No.	
		PCT/US02/26573	
	C200	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No.	
		PCT/US2004/005110	
	C201	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110	
	C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by	
		ADP-affinity chromatography" J. Immunol. Meth. 204:13	
	C203	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4	
		Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667	
	C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4	
	C205		
	6203	heat shock protiens", Nature Vol 320 (13) 182-184	
	C205	• • • • • • • • • • • • • • • • • • •	
	0200	oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787	
	C207	PREHN AND MAIN, 1957 "Immunity To Methylcholanthrene-Induced Sarcomas." J. Natl. Cancer Inst.	
	020.	18:769-778	
	C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82	_
	C209		
	C209	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol. 3(2):139-54	
	C210	to the contract of the contrac	
	C210		
		in treated patients." Thromb Haemost. 64(2):276-80.	
	C211	REPMANN et al. 1997 "Adjuvant Therapy Of Renal Cell Carcinoma With Active-Specific-	
		Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882	
	C212	REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis	
		and Related Techniques, December 1984	
	C213	ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated	
		transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-	
	1	induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796	

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
	APPLICANT		
	Srivastava et al.		_
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

	NON PATENT LITERATURE DOCUMENTS	
C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related Processes in Cells", Cell 59:591-601	
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized by Cytotoxic T cells", <i>Nature</i> 348:248-251	
C216		
C217	SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272	
C218	SALLUSTO et al., 1994, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118	
C219	SANO et al., 1987, "The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184	
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434	
C221		<u> </u>
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706	
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HI A Class I and Class II." J. Immunol, 173:1987-1993	
C224	SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis", Immunology 82(2):244-8	
C225	SINGH, 1997, "Neuroautoimmunity: pathogenic implications for Alzheimer's disease," Gerontology 43:79-94	
C228	SMORODIN et al., 1991, "The complex of $\alpha$ -2 Macroglobulin with CD2 in the Plasma of Gastric Carcinoma Patients." Scand J. Immunol 33:699-706	
C221		
C228		
C228		
C230		
C231		
C232		
C233		
C234		

EXAMINER	DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

C235	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma
0235	is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically
	induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
C237	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse
322.	tumors," Immunol. Today 9:78-83
C238	
	Antigen GP96," Cancer Res. 49:1341-1343
C239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
C240	
	protein GP96: Implications for vaccination against cancer and infectious diseases", J Cell Biochem Suppl
	17D:94 (Abstract NZ014)
C241	
	adaptive world", Immunity 8(6):657-65
C242	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm",
	Experientia. (11-12):1054-60
C243	SRIVASTAVA, 1993, "Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in
	Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C244	
	Immunol. 2(3): 185-194
C245	
	cancer," Thorax 37(8):588-593
C246	STEINMAN, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic
	encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is
	the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex
4	improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
C248	
	Review
C249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered
	Vaccines 327:51-57
C250	
	histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C251	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in:
	Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.),
į į	Birkhauser/Springer, 77: 451-465
C252	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular
	immune responses to HIV-1" p24. J Immunol. 156(2):873-9
C253	TAILOR et al., 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A
	Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
C254	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
C255	
1 (233	I THE MICROR MANUAL OF Diagnosis and Therapy, 1777, Decis and Derkow cos., Meick Research

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in confor	mance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	ART UNIT 1643	

	NON PATENT LITERATURE DOCUMENTS
 C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
 C257	
	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	TWINING et al., 1977, "Large scale separation of protease inhibitors from malignant human breast
	tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96,
	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the
	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein,"
	Proc. Natl. Acad. Sci. USA 83(10):3121-3125
 C262	URBANIAK AND ROBINSON, 1990, "ABC of transfusion. Therapeutic apheresis," BMJ
	300(6725):662-5 Review
C263	VAAGE, 1968 "Nonvirus-Associated Antigens In Virus-Induced Mouse Mammary Tumors." Cancer Res.
	<u>28</u> :2477-2483
C264	VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of
	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
C265	VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse
100	b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
C266	WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility
	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	
	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
	497
C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of
	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
 C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem.
52.1	257:14949-14959
 C272	
	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes
	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
	fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	
 C275	WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin
	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	
	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment
	of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.	
	8449-178-999	09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT		
	Srivastava et al.	· · · · · · · · · · · · · · · · · · ·	_
	FILING DATE	ART UNIT	
	June 4, 2001	1643	

	NON PATENT LITERATURE DOCUMENTS
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" <i>Int. J. Mol. Med.</i> 3:243
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627
C282	
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.

EXAMINER

DATE CONSIDERED

box 3 of 3

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 1 of 9 of List of References

ATTY. DOCKET NO.

8449-178-999

O9/873,403

APPLICANT

(New 2007

APPLICANT

Srivastava et al.

FILING DATE

June 4, 2001

APPLICATION NO.

109/873,403

ART UNIT

1643

	NONEDATION LEVEL ATLIDE DOCUMENTS
	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	HOUGHTEN et al., 1991, "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," Science 354:84-86
C103	
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
C105	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
C107	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	ISRAELI et al., 1993, "Molecular Cloning Of A Complementary DNA Encoding A Prostate-Specific Membrane Antigen." Cancer Res. 53:227-230
C111	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
C113	Biol. Sci. p.43-47
C114	protein gp96 preparations; a pilot study" Int. J. of Cancer 88:232-238
	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	JINDAL et al., 1989, "Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.		
	FILING DATE June 4, 2001	art unit 1643	

	NON PATENT LITERATURE DOCUMENTS
C119	Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	KATSUTANI et al., 1992, "Immunogenic properties of structurally modified human tissue plasminogen activators in chimpanzees and mice." Fundam Appl Toxicol.19(4):555-62.
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	KOJIMA et al., 2002, "Combination therapy of tumor-derived gp96 and GM-CSF or IL-12-gene transduced tumor cells in the control of LLC tumor," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, Abstract #5516
C124	is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	mice." Cancer Res. 42(5):1788-97
C126	
C127	53:1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
C130	
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
C132	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	folding and antigen presentation", EMBO J. 12(8):3143-3151
C134	Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
C135	Freeman and Company 2000
C136	Molecules", Nature 351:72-77
C137	LUKACS et al., 1993, "Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors", J. Exp. Med. 178:343-348
C138	21(10):2297-302
C139	MADDEN et al., 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", <i>Nature</i> 353:321-325

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	атту. доскет no. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE Tupe 4 2001	ART UNIT

	NON PATENT LITERATURE DOCUMENTS
C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University
C141	MARTIN et al., 1986, "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research 46:2189-2192
C142	
C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression", Nat. Med. 5:581-7
C144	
C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American Society for Microbiology pp. 1-13
C146	MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an idea whose time has come" Semin. in Oncology 25:654
C147	MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7
C148	MILLWARD AND HOELTGE, 1982, "The Historical Development of Automated Hemapheresis", J. of Clin. Apheresis 1: 25-32
C148	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer," Biotherapy 10:173-185
C150	MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen", Exper. Cell Res. 190: 195-203.
C151	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.
C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490
C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."
C154	Recombinant Interleukin-2", Science 225:1487-1489
C155	MUNRO et al., 1986, "An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein", Cell 46(2):291-300
C156	MURRAY et al., 1977 "Viral Oncolysate in the Management of Malignant Melanoma II, Clinical Studies." Cancer 40:680-686
C157	NAIR et al., 1977 "Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597
C158	
C159	

EXAMINER	DATE CONSIDERED
#EVARABLED. Initial if reference considered subother or not sitution is in conform	nance with MPEP 600. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

	NON PATENT LITERATURE DOCUMENTS	
C16	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the	
	stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139	
C16		
	Spring Harbor, NY pp. 387-394	
C16	* = = = * = = = = = = *	
	Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)	
C16		
	4 OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00	_
	5 OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00	_
C16	6 OFFICE ACTION mailed on 11/02/05 for U.S. Application No. 09/625,137 filed 07/25/00	
C16	7 OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00	
C16	8 OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00	
C16	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00	
C17	O OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00	_
C17	Properties of the Properties o	
C17		_
C17		
C17		
C17	5 OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00	_
	6 OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00	
C17		_
C17		
C17		
C18	O OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02	_
C18	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02	
C18	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03	
C18	3 OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05	
C18		
C18	5 OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04	
C18	6 OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04	_
C18	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164:558-561	_
C18		
C18		
C19	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis." Infect Immun. 60(11):4781-92	

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

	C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
		BALB/c sarcomas", Cancer Research 47:5074-5079
	C192	PARDOLL, 2000, "Therapeutic vaccination for cancer", Clin. Immunol. 95(1 Pt 2): S44-62
	C193	PATTILLO, 1974 "Combination Chemotherapy-Immunotherapy Indirect Chemotherapy Sensitivity
		Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and
·	<u></u>	Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
	C194	PAUL, Ed., 1993 Fundamental Immunology, 3rd Edition, Raven Press, NY, p. 1158 and References 189-
		220 Cited On pp.1173-1174
		PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
	C196	PCT International Preliminary Examination Report mailed on 01/16/06 for Intl. Application No.
		PCT/US03/14390
	C197	PCT International Preliminary Examination Report mailed on 06/17/03 for Intl. Application No.
		PCT/US01/23098
	C198	PCT International Preliminary Examination Report mailed on 09/23/04 for Intl. Application No.
		PCT/US01/18041
	C199	PCT International Preliminary Examination Report mailed on 10/06/2005 for Intl. Application No.
		PCT/US02/26573
	C200	PCT International Preliminary Examination Report mailed on 10/11/06 for Intl. Application No.
		PCT/US2004/005110
		PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
	C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by
		ADP-affinity chromatography" J. Immunol. Meth. 204:13
	C203	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4
		Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
	C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
	C205	PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major
		heat shock protiens", Nature Vol 320 (13) 182-184
	C206	······································
		oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
	C207	
		18:769-778
	C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
	C206	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol.
	C20 <b>0</b>	3(2):139-54
	C210	
	C210	in treated patients." Thromb Haemost. 64(2):276-80.
	C211	1
		Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
	C212	
		and Related Techniques, December 1984
	C213	ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated
		transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene- induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796

#### EXAMINER

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

6214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related
C214	Processes in Cells", Cell 59:591-601
C215	
(213	by Cytotoxic T cells", Nature 348:248-251
C216	
02.10	including H-4 and H-Y" Science 249: 283-287
C217	
C218	
	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by
	tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118
C219	
	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-
100	reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary
	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med.
_	191:423-434
C221	SCHREIBER, 1989 "Tumor Immunology." In: Fundamental Immunology, 2nd Edition, Paul, ed., pp;
	923-955
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706
C223	
	HLA Class I and Class II," J. Immunol. 173:1987-1993
C224	SILVA et al., 1994, "A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting
	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C225	
	43:79-94
C224	
	Carcinoma Patients." Scand J. Immunol 33:699-706
C227	
	hsp90", J. Mol. Biol. 194(2):341-4
C228	
	Acta. Neurol. Scand. 98(5):314-7  SPARKS et al., 1976, "Immunology and adjuvant chemoimmunotherapy of breast cancer," Arch. Surg.
C224	
G226	111:1057-1062
C230	
C221	Surgical Procedures," 19-22
C231	SRIVASTAVA and HEIKE, 1986, "Tumor-specific immunogenicity of stress-induced proteins: Convergence of two evolutionary pathways of antigen presentation?", Seminars in Immunology 3:57-64
0000	
C232	
	Tumor Antigens and Specific Tumor Therapy, pages 63-71  SRIVASTAVA and UDONO, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy"
C233	
	Curr. Opin. Immunol. 6:728  SRIVASTAVA et al. (1990) "Immunization with Soluble Gp96 Antigens Elicits Tumor-Specific Cellular
C234	1 SKIVAS 1 A V A et al. (1990) Immunization with soluble Gp90 Antigens Efficies Tumor-Specific Centual

		Immunity:, Cellular Immunity and the Immunot		
EXAMINE	R		DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	I	
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

		NON PATENT LITERATURE DOCUMENTS
	C235	SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma
		is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
	C236	SRIVASTAVA et al., 1987, "5'-structural analysis of genes encoding polymorphic antigens of chemically
		induced tumors." Proc. Natl. Acad. Sci USA 84(11):3807-3811
	C237	SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse
		tumors," Immunol. Today 9:78-83
_	C238	SRIVASTAVA et al., 1989, "Identification of a Human Homologue of the Murine Tumor Rejection
		Antigen GP96," Cancer Res. 49:1341-1343
	C239	SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
	C240	SRIVASTAVA et al., 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock
		protein GP96: Implications for vaccination against cancer and infectious diseases", J Cell Biochem Suppl
		17D:94 (Abstract NZ014)
	C241	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an
		adaptive world", Immunity 8(6):657-65
	C242	SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm",
		Experientia. (11-12):1054-60
	C243	
		Immune Response to Cancer and in Antigen Presentation," Adv. Cancer Res. 62:153-177
C244 SRIVASTAVA, 2002, "Roles of heat-shock proteins in innate and adaptive immunity," Nature Rev.		
		Immunol. 2(3): 185-194
	C245	
		cancer." Thorax 37(8):588-593
	C246	STEINMAN, L., 2001, "Myelin-specific CD8+ T cells in the pathogenesis of experimental allergic
		encephalitis and multiple sclerosis," J. Exp. Med. 194:F27-F30
	C247	STENMAN et al., 1991, "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is
		the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex
		improves clinical sensitivity for cancer," Cancer Res. 51(1):222-6
	C248	STEVENSON, 1999, "DNA vaccines against cancer: from genes to therapy," Ann. Oncol. 10:1413-8
		Review
	C249	SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered
		Vaccines 327:51-57
	C250	SUZUE et al., 1997, "Heat shock fusion proteins as vehicles for antigen delivery into the major
		histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
	C251	SUZUE K., Young R.A., 1996, "Heat shock proteins as immunological carriers and vaccines. in:
		Stress-Inducible Cellular Responses" (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.),
		Birkhauser/Springer, 77: 451-465
	C252	10000 1 1 1
		immune responses to HIV-1" p24. J Immunol. 156(2):873-9
	C253	TAILOR et al., 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A
		Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
	C254	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
	C255	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research
		Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

1 0055	THOMAS -4 -1 1092 "Malacular and Callular Efforts of Host Shock and Dalated Treatments of
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of
6057	Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996  TODRYK et al., 1999, "Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines
C257	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
60.50	
C258	
G250	tissue," Mol. Cell. Biochem. 18(2-3):101-7  UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96,
C259	hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	
C200	tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	
(201	Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	
0202	300(6725):662-5 Review
C263	
6265	28:2477-2483
C264	
020.	the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
C265	
	b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
C266	
	complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as
	cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-
	497
C268	
	ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
C270	
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem.
/.	257:14949-14959
C272	
	Proteins for Nucleotides", Mol. Cell. Biol. 5:1229-1237
C273	WELCH et al., 1995, "Morphological study of the mammalian stress response: characterization of changes
	in cytoplasmic organelles, cytoskeleton, and nucleoli, and appearance of intranuclear actin filaments in rat
	fibroblasts after heat-shock treatment," J. Cell. Biol. 101:1198-1211
C274	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
C276	
	in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	
	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment
	of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform considered. Include copy of this form with next communication to applicant.	nance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: ED 608 969 361 US

Sheet 9 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.	
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540	
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" <i>Int. J. Mol. Med.</i> 3:243	
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627	
C282	ZIMECKI et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals." Arch Immunol Ther Exp (Warsz). 46(4):231-40.	
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.	

EXAMINER

DATE CONSIDERED



ATTY. DOCKET NO.



box 3 of 3

Express Mail No.: ED 608 969 361 US Sheet 1 of 9 of List of References

APPLICATION NO.

	8449-178-999	09/873,403	
FOF REFERENCES CITED BY APPLICANT	APPLICANT		
(Use several sheets if necessary)	Srivastava et al.		
<u>&amp;</u> \	FILING DATE	ART UNIT	
3 2007 Bio	June 4, 2001	1643	

	NON PATENT LITERATURE DOCUMENTS
C98	HINDS et al., 1990, "Mutant p53 DNA Clones from Human Colon Carcinomas Cooperate with ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes" Cell Growth and Differentiation Vol. 1 571-580
C99	HOLLINSHEAD, 1988, "Immunotherapy," in: Cancer: The Outlaw Cell, LaFond, ed., American Chemical Society, Washington, DC pp. 237-250 (Chapter 14)
C100	HORN et al., 1995, "Analysis of the binding of Pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library", J. of Biol. Chem. 270 (20): 11770-11775.
C101	HORWITZ et al., 1995, Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 92(5):1530-4
C102	
C103	HUBBARD et al., 1992, "Immunization of mice with mycobacterial culture filtrate proteins," Clin. Exp. Immunol. 87(1):94-8
C104	HUGHES et al., 1970, "A Study In Clinical Cancer Immunotherapy", Cancer, 26:269-278
C105	
C106	HUMPHREY et al., 1984, "Adjuvant immunotherapy for melanoma," J. Surg. Concol. 25:303-305
C107	HUNTER, N. et al., 1991, "Suppression of experimental allergic encephalomyelitis by alpha(2)-macroglobulin," Immunology 73:58-63
C108	ISAACS et al., 1988, "Use of anti-idiotypic antibodies to establish that monoclonal antibody 7H11D6 binds to the alpha2-macroglobulin receptor recognition site", J. Biol. Chem. 263(14): 6709-6714.
C109	ISHII et al., 1999, "Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96", J Immunol. 162(3):1303-9
C110	
CIII	JAIN et al., 1994, "Barriers to drug delivery in solid tumors." Sc Am 171(1):58-65
C112	JAKOB et al., 1993, "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520
C113	Biol. Sci. p.43-47
	JANETZKI et al., 2000, "Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study" Int. J. of Cancer 88:232-238
C115	JANEWAY, Travers, Walport, and Shlomchick, 2001, Immunobiology, 5th ed., Garland Publishing, New York (Part V, Sections 13-1 to 13-15)
C116	JARDETZKY et al., 1991, "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329
C117	plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol. 9(5):2279-83
C118	

DATE CONSIDERED **EXAMINER** 

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 2 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	
	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

	NON PATENT LITERATURE DOCUMENTS
C119	KATSANIS et al., 2000, "Augmentation of Tumor Lysate Immunogencity by enrichment of Chaperone Proteins Using Free Solution Isoelectric Focusing (FS-IEF)" Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, abstract 431
C120	
C121	KIM et al., 1998, "A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognized apolipoprotein E", J. Biochem. 124: 1072-1076.
C122	KIMBER et al., 2002, "Lactoferrin: influences on langerhans cells, epidermal cytokines, and cutaneous inflammation." Biochem Cell Biol. 2002;80(1):103-7.
C123	transduced tumor cells in the control of LLC tumor," AACR 93 <sup>rd</sup> Annual Meeting, Vol. 43, Abstract #5516
C124	is an essential receptor for HSP60 activation of monomuclear cells", J Immunol. 164(1):13-17
C125	mice," Cancer Res. 42(5):1788-97
C126	KORNFELD et al., 1980, "Plasmapheresis in Myasthenia Gravis," Plasma Therapy, 2(3): 127-133
C127	<u>53</u> :1333-1336
C128	protein (LRP) is the alpha 2-macroglobulin receptor", FEBS Lett. 276(1-2):151-5
C129	KUHLMANN et al., 1997, "Drug Research: from the idea to the product," International Journal of Pharmacology and Therapeutics 35:541-552
	LAKEY et al., 1987, "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci. USA 84:1659-1663
C131	LANZAVECCHIA, 1993, "Identifying Strategies for Immune Intervention", Science 260:937-944
	LÉVY, 1991, "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274
C133	LI and SRIVASTAVA, 1993, "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", <i>EMBO J.</i> 12(8):3143-3151
C134	Lysates of Autologous and Allogeneic Cultured Melanoma Cells." Cancer, 55:713-720
	LODISH et al., <i>Molecular Cell Biology</i> , ch. 17.3 "Overview of the Secretory Pathway". pp 691-696, W.H. Freeman and Company 2000
C136	LUESCHER et al., 1991, "Specific Binding of Antigenic Peptides to Cell-associated MHC Class I Molecules", Nature 351:72-77
C137	induce protection against tumors", J. Exp. Med. 178:343-348
C138	LUSSOW et al., 1991, "Mycobacterial heat-shock proteins as carrier molecules", Eur J Immunol. 21(10):2297-302
C139	MADDEN et al., 1991, "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", <i>Nature</i> 353:321-325

EXAMINER		DATE CONSIDERED
*FXAMINER	Initial if reference considered, whether or not citation is in conform	nance with MPEP 609: Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 3 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

		NON PATENT LITERATURE DOCUMENTS	
<del></del>	C140	MAKI (1991) "The Human Homologue of the Mouse Tumor Rejection Antigen GP96", Ph.D. thesis, Cornell University	
	C141		_
	C142	MATSUTAKE et al., 2001, "The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein," PNAS 98(7):3992-3997	
	C143	MELCHER et al., 1998, "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression", Nat. Med. 5:581-7	
	C144	MELIEF et al., 1992, "Lessons from T Cell Responses to Virus Induced Tumours for Cancer Eradication in General", Career Surveys 13:81-99	
	C145	MELNICK, 1985, "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 November 1984, American Society for Microbiology pp. 1-13	
		MÉNORET and CHANDAWARKAR, 1998, "Heat-shock protein-based anticancer immunotherapy: an idea whose time has come" Semin. in Oncology 25:654	
		MENORET et al., 1995, "Co-segregation of tumor immunogenicity with expression of inducible but not constitutive hsp70 in rat colon carcinomas," J. Immunol. 155:740-7	
		MILLWARD AND HOELTGE, 1982, "The Historical Development of Automated Hemapheresis", J. of Clin. Apheresis 1: 25-32	
	C149	MIZZEN et al., 1998, "Immune responses to stress proteins: applications to infectious disease and cancer," Biotherapy 10:173-185	
	C150	MOESTRUP et al., 1990, "Immunocytochemical identification of the human aplpha 2-macroglobulin receptor in monocytes and fibroblasts: monoclonal antibodies define the receptor as a monocyte differentiation antigen", Exper. Cell Res. 190: 195-203.	
	Cisi	MOESTRUP et al., 1991, "Analysis of Ligand Recognition by the purified alpha-2M- macroglobulin receptor (low density lipoprotein receptor-related protein). J. Biol. Chem. 266(21):14011-14017.	
	C152	MOROI et al., 2000, "Induction of Cellular Immunity by Immunization with Novel Hybrid Peptides Complexed to Heat Shock PRotein 70." Proc. Natl. Acad. Sci. 97(7):3485-3490	
	C153	MSNBC News Services, 2000, "Mixed Results on new cancer drug."	
	C154	Recombinant Interleukin-2", Science 225:1487-1489	
	C155	MUNRO et al., 1986, "An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein", Cell 46(2):291-300	
	C156		
	C157	NAIR et al., 1977 "Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are Potent Tumor Vaccines." Eur. J. Immunol. 27:589-597	
	C158		
	C159		

EXAMINER		DATE CONSIDERED
*EYAMINED.	Initial if reference considered, whether or not citation is in conform	nance with MPEP 609. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 4 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
8449-178-999

APPLICANT

Srivastava et al.

FILING DATE
June 4, 2001

APPLICATION NO.
109/873,403

C160	NIELAND et al., 1996, "Isolation of an immunodominant viral peptide that is endogenously bound to the
 	stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139
C161	NORRBY, 1985, "Summary," in: Vaccines 85, Lerner et al., eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY pp. 387-394
C162	OETTGEN AND OLD, 1991 "The History Of Cancer Immunotherapy." In: Introduction To The Biologic Therapy Of Cancer", Devitta et al., Eds., Lippincott, Philadelphia, PA, pp.87-119 (Chapter 6)
 C163	OFFICE ACTION mailed on 02/26/02 for U.S. Application No. 09/625,137 filed 07/25/00
C164	OFFICE ACTION mailed on 05/18/05 for U.S. Application No. 09/625,137 filed 07/25/00
C165	OFFICE ACTION mailed on 10/05/04 for U.S. Application No. 09/625,137 filed 07/25/00
C166	
 C167	OFFICE ACTION mailed on 12/31/02 for U.S. Application No. 09/625,137 filed 07/25/00
 C168	OFFICE ACTION mailed on 02/08/06 for U.S. Application No. 09/668,724 filed 09/22/00
C169	OFFICE ACTION mailed on 02/25/03 for U.S. Application No. 09/668,724 filed 09/22/00
C170	OFFICE ACTION mailed on 05/07/02 for U.S. Application No. 09/668,724 filed 09/22/00
C171	OFFICE ACTION mailed on 06/20/07 for U.S. Application No. 09/668,724 filed 09/22/00
C172	OFFICE ACTION mailed on 07/07/04 for U.S. Application No. 09/668,724 filed 09/22/00
C173	OFFICE ACTION mailed on 09/21/06 for U.S. Application No. 09/668,724 filed 09/22/00
C173	OFFICE ACTION mailed on 03/13/06 for U.S. Application No. 09/750,972 filed 12/28/00
C175	OFFICE ACTION mailed on 06/05/02 for U.S. Application No. 09/750,972 filed 12/28/00
C176	OFFICE ACTION mailed on 08/28/03 for U.S. Application No. 09/750,972 filed 12/28/00
C177	OFFICE ACTION mailed on 01/11/06 for U.S. Application No. 10/225,367 filed 08/20/02
C178	OFFICE ACTION mailed on 03/30/05 for U.S. Application No. 10/225,367 filed 08/20/02
C178	OFFICE ACTION mailed on 04/18/07 for U.S. Application No. 10/225,367 filed 08/20/02
C180	OFFICE ACTION mailed on 09/25/06 for U.S. Application No. 10/225,367 filed 08/20/02
C181	OFFICE ACTION mailed on 10/19/07 for U.S. Application No. 10/225,367 filed 08/20/02
C182	OFFICE ACTION mailed on 01/03/06 for U.S. Application No. 10/427,857 filed 05/01/03
C183	OFFICE ACTION mailed on 10/15/07 for U.S. Application No. 10/546,106 filed 10/11/05
C184	OFFICE ACTION mailed on 02/22/07 for U.S. Application No. 10/784,012 filed 02/20/04
C185	OFFICE ACTION mailed on 08/07/06 for U.S. Application No. 10/784,012 filed 02/20/04
C186	OFFICE ACTION mailed on 11/02/07 for U.S. Application No. 10/784,012 filed 02/20/04
C187	OHASHI et al., 2000, Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 164:558-561
 C188	
	Tumors." Ann. N.Y. Acad. Sci. 101:80-106
C189	OPEKUN et al., 1999, "Novel therapies for Helicobacter pylori infection."
	Aliment Pharmacol Ther. 13(1):35-42.
 C190	PAL P.G., et al., 1992, "Immunization with extracellular proteins of Mycobacterium tuberculosis induces
	cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary

# \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 5 of 9 of List of References

	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Srivastava et al.	
	filing date June 4, 2001	ART UNIT 1643

C191	PALLADINO et al., 1987, "Expression of shared tumor-specific antigen by two chemically induced
	BALB/c sarcomas", Cancer Research 47:5074-5079
C192	
C193	
	Testing and Specific and Non-Specific Immunostimulation." In: Neoplasm Immunity: Theory and
	Application: Proceedings of a Chicago Sumposium, Crispen, Ed. ITR, Chicago, IL, pp. 189-204
C194	
	220 Cited On pp.1173-1174
	PAUL. Fundamental Immunology. 1993 Third Edition, Raven PRess, NY
C196	
	PCT/US03/14390
C197	
	PCT/US01/23098
C198	1
	PCT/US01/18041
C199	
	PCT/US02/26573
C200	
	PCT/US2004/005110
C201	PCT Written Opinion mailed on 10/11/06 for Intl. Application No. PCT/US2004/005110
C202	PENG et al., 1997, "Purification of immunogenic heat shock protein 70-peptide complexes by
	ADP-affinity chromatography" J. Immunol. Meth. 204:13
C203	PEREZ AND WALKER, 1989, "Isolation And Characterization Of A CcDNA Encoding The KS1/4
	Epithelial Carcinoma Marker", J. Immunol. 142:3662-3667
C204	PINEDA et al., 1994, "Applications of therapeutic apheresis," Mayo Clin. Proc. 69(9):893-4
C205	PINHASI-KIMHI et al. 1986, "Specific interaction between the p53 cellular tumour antigen and major
	heat shock protiens", Nature Vol 320 (13) 182-184
C206	
	oncogene breakpoint fusion peptides generates specific immune responses," Blood 95(5):1781-1787
C207	
	<u>18</u> :769-778
C208	PROUD, G. et al., 1979, "Blood transfusion and renal transplantation," Br. J. Sur. 66:678-82
C209	RAPLEY, 1995, "The biotechnology and applications of antibody engineering," Mol. Biotechnol.
(20)	3(2):139-54
C210	
10210	in treated patients." Thromb Haemost. 64(2):276-80.
C211	
	Immunotherapy (ASI) Using Autologous Tumor Vaccine." Anticancer Res. 17:2879-2882
C212	REPORT of the AMA Panel on Therapeutic Plasmapheresis, Current Status of Therapeutic Plasmapheresis
	and Related Techniques, December 1984
C213	ROGERS et al., 1981, "Some immunogenic acid biochemical properties of tumor-associated
	transplantation antigens (TATA) obtained in soluble form or solubilized from two methylcholanthrene-
	induced sarcomas, Meth A and CI-4," Int. J. Cancer 27:789-796

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conform	nance with MPEP 609; Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication to applicant.	

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 6 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

C214	ROTHMAN, 1989, "Polypeptide Chain Binding Proteins: Catalysts of Protein Folding and Related
	Processes in Cells", Cell 59:591-601
C215	RÖTZSCHKE et al., 1990, "Isolation and Analysis of Naturally Processed Viral Peptides as Recognized
	by Cytotoxic T cells", Nature 348:248-251
C216	
6217	including H-4 and H-Y" Science 249: 283-287  SALK et al., 1993, "A Strategy for Prophylactic Vaccination Against HIV", Science 260:1270-1272
C217	
C218	maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha," J. Exp. Med. 179(4):1109-1118
C219	
(21)	(MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity," Cancer Immunol. Immunother. 25(3):180-184
C220	SAUTER et al., 2000, "Consequences of cell death: exposure to necrotic tumor cells, but not primary
	tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells", J. Exp. Med. 191:423-434
C223	SCHREIBER, 1989 "Tumor Immunology." In: Fundamental Immunology, 2nd Edition, Paul, ed., pp; 923-955
C222	SCHUMACHER et al., 1991, "Peptide Selection by MHC Class I Molecules", Nature 350:703-706
C223	SENGUPTA et al., 2004, "Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA Class I and Class II," J. Immunol. 173:1987-1993
C223	cell vaccinates mice against tuberculosis", Immunology 82(2):244-8
C223	43:79-94
C226	Carcinoma Patients." Scand J. Immunol 33:699-706
C227	SORGER and PELHAM, 1987, "The glucose-regulated protein grp94 is related to heat shock protein hsp90", J. Mol. Biol. 194(2):341-4
C223	SOTGIU et al., 1998, "Genetic susceptibility to multiple sclerosis in Sardinians: an immunological study," Acta. Neurol. Scand. 98(5):314-7
C22	111:1057-1062
C230	SPERO et al., 1980, "Plasma Exchange in Preparation of Mild Factor IX Deficient Hemophiliacs for Surgical Procedures," 19-22
C231	
C232	SRIVASTAVA and OLD (1989) "Gp96 Molecules: Recognition Elements in Tumor Immunity", Human
C233	Tumor Antigens and Specific Tumor Therapy, pages 63-71  SRIVASTAVA and UDONO, 1994, "Heat shock protein-peptide complexes in cancer immunotherapy"
1 2233	Curr. Opin. Immunol. 6:728
C234	

EXAMINER	DATE CONSIDERED
	with MDED 600. Draw line through citation if not in conformance and not

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 7 of 9 of List of References

	ATTY. DOCKET NO.	APPLICATION NO.
	8449-178-999	09/873,403
LIST OF REFERENCES CITED BY APPLICANT	APPLICANT	
(Use several sheets if necessary)	Srivastava et al.	
	FILING DATE	ART UNIT
	June 4, 2001	1643

	NON PATENT LITERATURE DOCUMENTS
C23	5 SRIVASTAVA et al., 1984, "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is also its Tumor-Associated Transplantation Antigen", Int. J. Cancer 33:417-422
C23	
C23	7 SRIVASTAVA et al., 1988, "Individually distinct transplantation antigens of chemically induced mouse tumors," Immunol, Today 9:78-83
C23	
C23	9 SRIVASTAVA et al., 1991, "Protein Tumor Antigens", Curr. Opin. Immunol. 3:654-658
C24	SRIVASTAVA et al., 1993, "Evidence for peptide-chaperoning by the endoplasmic reticular heat shock protein GP96: Implications for vaccination against cancer and infectious diseases", <i>J Cell Biochem Suppl</i> 17D:94 (Abstract NZ014)
C24	SRIVASTAVA et al., 1998, "Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world". Immunity 8(6):657-65
C24	2 SRIVASTAVA PK, 1994, "Heat shock proteins in immune response to cancer: the Fourth Paradigm", Experientia. (11-12):1054-60
C24	
C24	9 SUBBARAO et al., 1992, "A General Overview of Viral Vaccine Development," Genetically Engineered Vaccines 327:51-57
C2	histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA 94(24):13146-51
C2.	
C2	SUZUE K., Young R.A., 1996, "Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1" p24. J Immunol. 156(2):873-9
C2	TAILOR et al., 1990, "Nucleotide Sequence Of Human Prostatic Acid Phosphatase Determined From A Full-Length cDNA Clone." Nucl. Acids Res. 18:4928 (1990)
C2.	TAIT, BD, 1990, "Genetic susceptibility to type I diabetes: a review," J. Autoimmun. 3 Suppl. 1:3-11
C2.	THE MERCK MANUAL of Diagnosis and Therapy, 1999, Beers and Berkow eds., Merck Research Laboratories, Whitehouse Station N.J., pp. 1871 and 1872

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 8 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	art unit 1643

	NON PATENT LITERATURE DOCUMENTS
C256	THOMAS et al., 1982, "Molecular and Cellular Effects of Heat Shock and Related Treatments of Mammalian Tissue-Culture Cells", Cold Springs Harbor Symp Quant Biol 46:985-996
C257	and targets immature dendritic cell precursors to enhance antigen uptake," J. Immunol. 163:1398-1408
C258	tissue," Mol. Cell. Biochem. 18(2-3):101-7
C259	UDONO et al., 1994, "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol., 152(11):5398-5403
C260	UDONO, 1993, "Heat shock proteins HSP70, HSP90 and GP96 elicit tumor specific immunity to the tumors from which they are isolated", J. Cell. Biochem. Suppl. 17D:113 (Abstract NZ225)
C261	ULLRICH et al., 1986, "A mouse tumor-specific transplantation antigen is a heat shock-related protein," Proc. Natl. Acad. Sci. USA 83(10):3121-3125
C262	
C263	The state of the s
C264	VANBUSKIRK et al., 1989, "Peptide binding protein having a role in antigen presentation is a member of the hsp70 heat shock family", J. Exp. Med. 170:1799-1809
C265	VIJAYASARADHI et al., 1990 "The Melanoma Antigen gp75 Is The Human Homologue Of The Mouse b (Brown) Locus Gene Product." J. Exp. Med. 171:1375-1380
C266	WALLNY et al., 1992, "Gene transfer experiments imply instructive role of major histocompatibility complex class I molecules in cellular peptide processing". Eur. J. Immunol 22:655-659
C267	WANG et al., 2001, "Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity," J. Immunol. 166(1):490-497
C268	WARSHAWAKY et al., 1993, "Identification of domains in the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein," J. Biol. Chem. 268(29):22046-22054.
C269	WEINER et al., 1980, "Plasmapheresis in multiple sclerosis: preliminary study," Neurology 30: 1029-33
C270	WEINER et al., 2002, "Inflammation and therapeutic vaccination in CNS diseases," Nature 420:879-884
C271	WELCH et al., 1982, "Purification of the Major Mammalian Heat Shock Proteins", J. Biol. Chem. 257:14949-14959
C272	
C273	
C274	WELCH, 1993, "How Cells Respond to Stress," Scientific American 268(5):56-64
C275	WILLNOW et al., 1996, "The low-density-lipoprotein receptor-related protein (LRP) is processed by furin in vivo and in vitro." The Biochemical Journal. England 313:71-76
C276	on chromosome 11," Clin. Exp. Immunol. 83(1):69-73
C277	XIAO et al., 1995, "Characterization of hormonogenic sites in an N-terminal, cyanogen bromide fragment of human thyroglobulin." Arch Biochem Biophys. 20;320(1):96-105

#### **EXAMINER**

DATE CONSIDERED

Express Mail No.: <u>ED 608 969 361 US</u> Sheet 9 of 9 of List of References

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 8449-178-999	APPLICATION NO. 09/873,403
	APPLICANT Srivastava et al.	
	FILING DATE June 4, 2001	ART UNIT 1643

NON PATENT LITERATURE DOCUMENTS		
C278	YAMAUCHI et al., 2000, "Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study." Mycoses.43(5):197-202.	
C279	YANG et al., 1999, "Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8+ and CD4+ T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity," Int. J. Cancer 83:532-540	
C280	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model" Int. J. Mol. Med. 3:243	
C281	YU et al., 1991, "Sequence Analysis of Peptides Bound to MHC Class II Molecules", Nature 353:622-627	
C282	ZIMECKI et al., 1998, "Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals." Arch Immunol Ther Exp (Warsz). 46(4):231-40.	
C283	ZIMECKI et al., 1999, "Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells." Arch Immunol Ther Exp (Warsz). 47(2):113-8.	

EXAM	INER
22 2 2 2 2 V I	****

DATE CONSIDERED